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Necroptosis is a caspase-independent form of regulated cell death executed via 
activation of receptor interacting protein 1 (RIP1) and RIP3, being negatively regulated by 
caspase-8. Neurodegenerative diseases are hereditary or sporadic conditions characterized 
by progressive cell death in selected areas of the nervous system, along with oxidative 
stress, mitochondrial dysfunction and neuroinflammation. Importantly, recent studies have 
demonstrated that necroptosis is involved in the pathogenesis of several disorders, including 
neurodegenerative diseases. 
Neuroinflammation, in turn, is a response to eliminate the original insult and 
damaged or dead cells. However, if tissue physiology is not restored, inflammation becomes 
a chronic condition, where microglia plays a major role. Studies have shown that defects in 
caspase-8 activation in microglia may promote inflammation through activation of 
necroptosis.  
In the present study, we used the murine BV2 microglia cell line as an in vitro 
model to screen a library of novel compounds, potential modulators of necroptosis, and 
evaluate if necroptosis modulation may contribute to attenuate microglia-mediated 
inflammation. Importantly, we identified one hit Oxa12 that inhibits this type of regulated cell 
death by preventing all necroptosis-associated events, including RIP1/RIP3 necrosome 
assembly, and MLKL phosphorylation. In addition, Oxa12 decreased TNF-α gene expression 
and secretion as well as JNK and p38 MAPK activation, while IκB phosphorylation was 
increased.  
In conclusion, we established a robust in vitro model of microglia necroptosis and 
identified a strong inhibitor of this regulated form of cell death that might be a promising 
































A necroptose é um tipo de morte celular regulada e independente de caspases, 
que ocorre quando há ativação das proteínas receptor interacting protein 1 (RIP1) e RIP3, 
sendo inibida pela caspase-8. As doenças neurodegenerativas são condições hereditárias 
ou esporádicas caracterizadas pela ocorrência de morte celular progressiva em áreas 
específicas do sistema nervoso, assim como pela existência de stress oxidativo, disfunção 
mitocondrial e neuroinflamação. É importante referir que estudos recentes têm demonstrado 
que a morte celular por necroptose está envolvida na patogénese de várias doenças, 
incluindo as doenças neurodegenerativas. 
A neuroinflamação, por sua vez, visa eliminar tanto a causa inicial do dano 
celular, como as células mortas que resultam do insulto original. Contudo, se a fisiologia 
normal do tecido não for restaurada, a inflamação torna-se uma condição crónica. No 
sistema nervoso central (CNS), são as células da microglia que constituem a primeira linha 
de defesa, desempenhando um papel crucial na neuroinflamação, através da contínua 
produção de citoquinas pró-inflamatórias e espécies reativas de oxigénio, entre outros. 
Estes mediadores inflamatórios podem, por sua vez, ter efeitos neurotóxicos. De facto, a 
comunicação entre a microglia e os neurónios pode amplificar os sinais inflamatórios e 
contribuir para a patogénese das doenças neurodegenerativas. De salientar que, tal como 
descrito recentemente, a inativação de caspase-8 na microglia pode promover inflamação 
através da ativação da necroptose.  
No presente estudo, foi utilizada a linha celular de microglia de murino, BV2, 
como um modelo in vitro para o estudo de duas bibliotecas de novos compostos, 
potencialmente moduladores da necroptose. Para além disso, avaliámos se a modulação da 
necroptose pode contribuir para atenuar a inflamação mediada pela microglia.  
Em primeiro lugar, otimizou-se o modelo celular. Os resultados obtidos 
demonstraram que a incubação de células BV2 com o inibidor de caspases, zVAD-fmk, 
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resultava em níveis elevados de morte celular por necroptose, tal como avaliado através de 
ensaios de viabilidade e citotoxicidade. Os resultados foram confirmados por Western blot, 
onde observámos um enriquecimento das proteínas RIP1 e RIP3 no proteoma insolúvel das 
células. Esta estrutura amiloide, ou necrossoma, desempenha um papel preponderante na 
ativação da necroptose. Pelo contrário, a incubação das células com o inibidor seletivo da 
atividade cinase da proteína RIP1, necrostatina-1 (Nec-1), reverteu totalmente a necroptose 
para níveis controlo.  
Após a otimização do modelo celular, testámos duas bibliotecas de compostos 
de famílias diferentes, onde identificámos a molécula Oxa12 como sendo capaz de inibir a 
necroptose na linha celular BV2. De facto, este composto reduziu os níveis de morte celular 
induzida por zVAD-fmk, em cerca de 80% (p < 0.05). Mais ainda, o composto Oxa12 
reprimiu todos os eventos associados à necroptose, incluindo a formação do necrossoma e, 
também, a fosforilação do resíduo de serina 358 da proteína MLKL pela proteína RIP3. É de 
salientar que a fosforilação da MLKL neste resíduo induz a sua oligomerização e 
consequente migração para a membrana plasmática, onde promove a rutura da mesma, 
sendo por isso um evento crítico na execução da necroptose. Podemos, assim, concluir que 
o composto Oxa12 é um inibidor forte da necroptose. De forma a melhor caracterizar a 
atividade do composto identificado, determinámos a concentração à qual tem metade da sua 
atividade máxima (EC50), assim como a sua toxicidade. Os resultados obtidos demonstraram 
que o composto Oxa12 inibe a necroptose com um EC50 de 1,422 µM, revelando o seu 
potencial, mesmo a concentrações reduzidas. Para além disso, verificámos que este 
composto não induz toxicidade em células BV2 controlo, ou seja, sem qualquer tratamento, 
mesmo a elevadas concentrações.  
A necroptose é considerada uma forma de morte celular do tipo inflamatório, 
devido à libertação dos constituintes intracelulares para o espaço extracelular onde se 
encontram células imunitárias, tais como macrófagos, que podem potenciar a inflamação. 
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Desta forma, a nossa hipótese foi a de que o composto Oxa12, ao inibir a necroptose, 
contribui para uma diminuição da inflamação. Assim, para além dos níveis dos transcritos de 
vários mediadores inflamatórios, tais como TNF-α, IL-1β, COX2 e NLRP3, avaliados por 
Real-Time PCR (RT-PCR), determinámos também os níveis de secreção de TNF-α, através 
da utilização de um ensaio de ELISA. Uma vez que a microglia constitui a principal linha de 
defesa do CNS, é bem conhecida a sua capacidade de produzir e libertar várias moléculas 
inflamatórias. Os resultados obtidos demonstraram que a incubação das células BV2 com 
zVAD-fmk resulta num aumento da transcrição dos genes TNF-α e IL-1β, assim como dos 
níveis de TNF-α secretados. Pelo contrário, a coincubação com Nec-1 foi capaz de reverter 
totalmente aqueles parâmetros. De particular importância é o facto do composto em estudo, 
Oxa12, ter diminuído os níveis de expressão e libertação de TNF-α. 
De forma a determinar quais as vias de sinalização especificamente moduladas 
pelo Oxa12, avaliámos os níveis de fosforilação de resíduos específicos das proteínas JNK 
(Treonina 183 e Tirosina 185) e p38 (Treonina 180 e Tirosina 182), componentes chave de 
duas vias de sinalização da família das MAP cinases. Os resultados revelaram um aumento 
significativo da fosforilação da proteína JNK, indicativos de ativação desta via, após 
incubação das células com zVAD-fmk, bem como a concomitante diminuição após adição de 
Nec-1 ou Oxa12. Estes resultados estão de acordo com os de outros autores, que referem a 
ativação da proteína JNK como um fator preponderante na indução da necroptose, 
nomeadamente promovendo a produção autócrina de TNF-α. Relativamente à proteína p38, 
a sua função na necroptose é ainda pouco conhecida, para além de contraditória. Enquanto 
alguns autores defendem que esta via de sinalização não interfere no mecanismo de morte, 
outros demonstraram que a inibição da necroptose induzida por TNF-α resulta na sua 
ativação. Curiosamente, os resultados obtidos neste trabalho revelaram um aumento dos 
níveis de p38 fosforilada após incubação das células com zVAD-fmk e, por sua vez, uma 
diminuição com Nec-1 ou Oxa12. É possível que este aumento de ativação com zVAD-fmk 
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esteja relacionado com a indução de respostas inflamatórias, uma vez que tanto a via da 
JNK como da p38 estão envolvidas na inflamação.  
Para além das vias de sinalização mediadas pela família das MAP cinases, 
avaliámos também os níveis de fosforilação da proteína Akt. Estudos recentes 
demonstraram que a inibição da proteína Akt é protetora num modelo de necroptose 
induzida por TNF-α em células L929. No entanto, outros estudos descrevem que o 
tratamento celular apenas com zVAD-fmk não é suficiente para induzir a fosforilação e, 
consequente, ativação da proteína Akt, sendo necessária a atividade conjunta de TNF-α e 
zVAD-fmk. Por outro lado, outros autores demonstraram que o zVAD-fmk é capaz de induzir 
a ativação da proteína Akt, sendo essa ativação dependente especificamente da fosforilação 
do resíduo Treonina 308. No nosso estudo, usámos um anticorpo especifico para a 
fosforilação do resíduo Serina 473, o que poderá justificar a ausência de diferenças 
significativas entre as condições estudadas. Por fim, fomos avaliar a ativação do fator de 
transcrição NF-κB, indiretamente, através dos níveis de fosforilação do seu inibidor IκB. Os 
nossos resultados demonstraram uma diminuição dos níveis de IκB fosforilado em células 
BV2 tratadas com zVAD-fmk e um aumento concomitante após adição de Nec-1 e Oxa12, 
sugerindo uma ativação daquele fator de transcrição. Estes resultados estão de acordo com 
os obtidos em estudos anteriores, confirmando que a via de sinalização mediada pelo NF-κB 
não possui um papel preponderante na ativação da necroptose ou na expressão de TNF-α. 
Para além disso, é ainda possível que o composto Oxa12 promova um desvio da sinalização 
da necroptose para vias de sobrevivência celular mediadas pelo NF-κB. No entanto, são 
necessários mais estudos que confirmem esta hipótese. 
Em conclusão, estabelecemos um modelo celular robusto de necroptose em 
microglia e identificámos um forte inibidor químico deste tipo de morte celular regulada. O 
composto Oxa12 é um candidato promissor para ser utilizado na terapêutica de patologias 
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Dementia is a clinical syndrome characterized by progressive deterioration in 
cognitive ability and capacity for independent living (Prince M et al, 2013). The global 
incidence of dementia places a considerable burden on society, since overall life expectancy 
has greatly increased. Indeed, aging populations worldwide face a growing problem of 
neurodegenerative diseases (Organization WH, 2012). 
 
1. Neurodegenerative diseases 
Neurodegenerative diseases are defined as hereditary or sporadic conditions 
characterized by progressive nervous system dysfunction. However, only an extremely small 
proportion (less than 5%) are caused by genetic mutations, with the remaining proportion 
being sporadic. These disorders are often associated with atrophy of the affected central or 
peripheral structures of the nervous system and include diseases such as Alzheimer’s 
disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and multiple 
sclerosis (MS), but also epilepsy, stroke and others. AD, PD and ALS are the major diseases 
in terms of mortality, morbidity, and health care costs. However, their triggering mechanisms 
are far from fully deciphered, and effective diagnosis and treatment are still highly 
demanded.  
Overall, the hallmarks of neurodegenerative diseases include cellular death in 
selected areas of the nervous system, as well as abnormal protein assemblies, oxidative 
stress, mitochondrial dysfunction and neuroinflammation. 
 
2. Neuroinflammation 
In addition to neurodegeneration, also neuroinflammation has been implicated in 
many central nervous system (CNS) diseases including acute brain damage and chronic 
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neurodegenerative disorders (Banati RB et al, 1998; Raine CS, 1994). Neuroinflammation is 
a complex cellular and molecular response to stress that attempts to contain the injury by 
way of clearing pathogens, dead or damaged host cells, and aid in returning the damaged 
area to its normal state. If tissue physiology is not restored, inflammation becomes a chronic 
condition. Of note, a characteristic feature of chronic inflamed tissues is the presence of an 
increased number of monocytes, as well as monocyte-derived tissue macrophages, called 
microglia cells in the CNS, in addition to an increased expression of acute phase proteins 
and proinflammatory cytokines which are hardly evident in the normal brain (Rubio-Perez JM 
et al, 2012). Microglia, astrocytes, neurons and the complementary system are all involved in 
the inflammatory reaction in the CNS. Although it was previously thought that the CNS was 
an immune-privileged site, due to its isolation from the immune system by the blood–brain 
barrier, the lack of draining lymphatics, and the apparent immunoincompetence of microglia, 
now it is known that certain features of the inflammatory process occur normally in response 
to injury, infection or disease (Rubio-Perez JM et al, 2012). More specifically, in response to 
brain injury, an inflammatory response mediated by microglia and astrocytes is induced, thus 
activating signaling pathways that may lead to neurodegeneration (Meraz-Ríos MA et al, 
2013) (Figure 1). Whether brain inflammation is a cause or a consequence of 
neurodegeneration is still a matter of debate.  
 
2.1. Microglia-mediated neuroinflammation  
Microglia are resident brain cells derived from monocyte precursors during 
embryogenesis. They constitute the main line of the innate immune defense in the CNS 
(Meraz-Ríos MA et al, 2013). In humans, microglia constitute up to 16% of the CNS cellular 





Figure 1. Neuroinflammation in AD. Amyloid-β (Aβ) aggregates activate microglia through toll-like 
receptors (TLRs) and receptors for advanced glycosylation end products (RAGE). These receptors, in 
turn, activate nuclear factor-κB (NF-κB) transcription factor, which induces reactive oxygen species 
(ROS) production and expression of proinflammatory cytokines interleukin (IL)-1β, IL-6, and tumor 
necrosis factor α (TNF-α). These inflammatory factors act on neurons and stimulate astrocytes, which 
amplify proinflammatory signals, inducing neurotoxic effects. Adapted from Meraz-Ríos MA et al, 
2013. 
 
Normally, microglia exist in an inactive or resting state, characterized 
morphologically by a small soma with branching processes (Norden DM et al, 2013). 
However, some studies have reported that microglia in the healthy CNS are not truly 
“resting”, since they are engaged in environment surveillance, constantly sampling areas 
around them in efforts to maintain homeostasis (Nimmerjahn A et al, 2005). Under 
pathological conditions, such as neurodegenerative diseases, these cells become activated, 
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migrate, surround damaged or dead cells, and subsequently clear cellular debris from the 
injured area (Rubio-Perez JM et al, 2011).  
Microglia possess several families of pattern recognition receptors (PRR), 
including specific toll-like receptors (TLRs) and receptors for advanced glycosylation end 
products (RAGE) that upon binding of conserved motifs of microbial and viral-derived 
molecules classified as pathogen-associated molecular patterns (PAMPs), activate 
downstream signaling cascades that culminate in microglial activation. In addition, several of 
these receptors are also involved in the recognition of distinct molecules released from 
endogenous compartments or modified in structure, such as abnormal protein aggregates, 
that constitute damage-associated molecular patterns (DAMPs) (Landreth GE et al, 2009; 
Heneka MT et al, 2014). Upon activation, microglia suffer visible morphological changes, with 
acquisition of an amoeboid form consisting in decreased branching and soma growth, and 
expression of a wide variety of specific cellular surface receptors and key enzymes, 
presenting increased phagocytic capabilities and secretion of inflammation-related molecules 
(Cherry JD et al, 2014). In the brain, this inflammatory response is fundamental to protect the 
CNS. However, uncontrolled or prolonged neuroinflammation is potentially harmful and can 
result in cellular damage, thus contributing to neurodegeneration (Frank-Cannin TC et al, 
2009).  
Several studies have led to the concept that, phenotypically, microglia can 
present different activation stages, ranging from “classical” activation (M1 activation) to 
“alternative activation” (M2 activation) (Cherry JD et al, 2014). Classically activated microglia 
are most commonly associated with disease states that are driven by inflammation, such as 
chronic inflammatory diseases, and leads to increased release of reactive oxygen species 
(ROS) and nitric oxide (NO), as well as production of proinflammatory mediators such as 
cytokines interleukin (IL)-1β, IL-6 and tumor necrosis factor α (TNF-α), which in turn are 
responsible for autocrine and paracrine inflammatory signaling in other glial cells and 
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neurons. Additionally, there is also increased production of chemokines such as IL-8 and 
monocyte chemoattractant protein 1 (MCP1), which can recruit other microglia and 
peripheral macrophages to the injury site. In contrast, alternative activation states are 
associated with protection from diseases and are classically stimulated by IL-4 and IL-13, 
being characterized by the repression of proinflammatory gene expression and increased 
production of neurotrophic factors and anti-inflammatory cytokines such as IL-10, 
transforming growth factor β (TGF-β), IL-4 and IL-13. This phenotype reduces inflammation, 
promotes phagocytosis and potentiates tissue repair (Lyman M et al, 2013; Meraz-Ríos MA 
et al, 2013). 
Microglia activation by abnormal protein aggregates, such as amyloid-β (Aβ) and 
α-synuclein (α-syn) aggregates, or by lipopolysaccharide (LPS), or even injury, promotes the 
stimulation of nuclear factor-κB (NF-κB)-dependent pathway that, in turn, is required for 
cytokine production. The subsequent activation of mitogen-activated protein kinase (MAPK) 
pathways may induce proinflammatory gene expression leading to the production of 
proinflammatory cytokines, chemokines and ROS (Rubio-Perez JM et al, 2011). Indeed, 
several studies have shown that the three MAPK pathways, extracellular signal-regulated 
kinase (ERK)1/2, c-Jun N-terminal kinase (JNK) and p38 are activated in stimulated-
microglia, thus contributing to TNF-α and IL-1β production (Kim EK et al, 2010). Conversely, 
others have demonstrated that microglia-induced production of ROS and proinflammatory 
cytokines can also stimulate MAPK signaling pathways, constituting a positive feedback loop 
(Kim EK et al, 2010). The proinflammatory mediators produced by classically activated 
microglia can then activate astrocytes and the products released by both cell types may exert 
neurotoxic effects. Therefore, communication between microglia and astrocytes and/or 
neurons can amplify the proinflammatory signals and contribute to the pathobiology of 
neurodegenerative diseases (Saijo K et al, 2011) (Figure 2). In fact, long-term inflammation 
can have disastrous consequences in the CNS, ranging from loss of synapses to impaired 
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cognition and overt neurodegeneration (Rao JS et al, 2012; Hein AM et al, 2009). In this 
regard, the therapeutic modulation of microglia-induced inflammation in the CNS may be a 
useful approach to prevent or attenuate disease progression. 
Figure 2. Classically activated microglia in neurodegenerative diseases. Several disease-
associated factors such as DAMPs and neurodegenerative disease-specific protein aggregates 
activate microglia through PRR to establish an M1-like microglial cell phenotype. Proinflammatory 
mediators produced by classically activated microglia activate astrocytes, and the products released 
by activated microglia and astrocytes may exert neurotoxic effects. Communication between microglia 
and astrocytes and/or neurons may therefore amplify proinflammatory signals initially sensed by 
microglia, and contribute to pathology of neurodegenerative diseases (Saijo K et al, 2011). 
 
2.2. Inflammatory mediators 
2.2.1. Cytokines 
Cytokines are a group of small and nonstructural soluble proteins with molecular 
weights ranging from 8 to 40 kDa secreted not only by a variety of immune cells but also by 
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nonimmune cells (e.g., Schwann cells or fibroblasts) (Rubio-Perez JM et al, 2012). Cytokines 
include TNFs, ILs and interferons (IFNs), among other molecules.  These molecules play an 
important role in CNS development during embryogenesis, being involved in the stimulation 
and inhibition of cell growth and differentiation, apoptosis, antiviral activity, upregulation of 
surface membrane proteins and inflammatory responses (Meraz-Ríos MA et al, 2013; Rubio-
Perez JM et al, 2012). However, they are also involved in the pathogenesis of several 
disorders, especially neurodegenerative diseases (Meraz-Ríos MA et al, 2013). Indeed, 
elevated levels of proinflammatory cytokines such as IL-1β, IL-6, and TNF-α have been 
reported in mouse models of AD, as well as in PD, ALS and MS patients, where they 
contribute to neurodegeneration (Jiang H et al, 2011; Patel NS et al, 2005).  
In other cases, proinflammatory cytokines might favor microglial and astrocytic 
activation to ultimately promote phagocytosis and neuronal survival. Nevertheless, chronic 
cytokine production is strongly related to neurodegeneration and strategies to tackle 
neuroinflammation are needed, possibly to be used as a therapeutic approach to attenuate 
neuronal death.  
 
TNF-α 
TNF-α is a pleiotropic cytokine that is present at increased levels in several 
neurodegenerative diseases (Montgomery SL et al, 2012; Liu S et al, 2014). It plays a central 
role in initiating and regulating the cytokine cascade during the inflammatory response 
(Rubio-Perez JM et al, 2012). Although astrocytes and neurons are able to produce TNF-α, it 
is assumed that microglia cells are the major source of this cytokine during 
neuroinflammation. However, since activated microglia may trigger different signaling 
pathways, including NF-κB and MAPKs, depending on the inflammatory stimuli, it is difficult 
to determine which pathway is indeed implicated in the induction of TNF-α expression 
(Olmos G et al, 2014). Moreover, TNF-α secreted by glial cells can activate them in an 
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autocrine manner and sustain cytokine production and astrogliosis. TNF-α is also involved in 
other cellular responses besides inflammation, including apoptosis and necrosis (Liu S et al, 
2014). Curiously, a recent study on MS showed that TNF-α released by necroptotic microglia 
is able to further induce necroptosis in oligodendrocytes in vitro, thus contributing to disease 
progression (Ofengeim D et al, 2015). 
 
IL-1 
The IL-1 family is a group of 11 cytokines basally expressed in the healthy CNS. 
IL-1α and IL-1β are the most studied members, because they were first discovered and also 
for their strong proinflammatory effects. Microglia and astrocytes are the primary source of 
IL-1β in the CNS (Toda Y et al, 2002); however, oligodendrocytes and neurons can also 
synthetize IL-1β and its signaling receptor (IL-1R) (Fogal B et al, 2008).  
IL-1β is implicated in the progression of chronic neurodegenerative diseases, 
such as AD and PD. In fact, this cytokine increases rapidly in response to stress or 
pathogenic invasion of the CNS (Rothwell NJ et al, 2000). Once secreted, IL-1β can 
stimulate its own production in an autocrine/paracrine manner and increase the expression of 
other relevant cytokines and proteins, such as IL-6, TNF-α and S100B (Kim SH et al, 2004). 
IL-1β has been reported to play an important role in neuronal degeneration through S100B 
present in reactive astrocytes. IL-1β also induces ROS and IL-6 production in astrocytes, 
thus stimulating inducible nitric oxide synthase (iNOS) activity that culminates in 




IL-6 is a potent pleiotropic cytokine mainly produced by activated microglia in 
different brain regions that can induce a strong inflammatory response (Lyman M et al, 
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2013). Importantly, significant high levels of IL-6 were found in patients with AD, PD, and MS. 
Like IL-1β, IL-6 can also stimulate the release of other proinflammatory cytokines and acute 
phase proteins, in microglia and astrocytes (Meraz-Ríos MA et al, 2013). Finally, this 
cytokine also plays a complex role in regulating cognitive function (Yirmiya R et al, 2011), 
since increased levels of IL-6 were associated with age-related cognitive decline (Weaver JD 
et al, 2002). 
 
2.3. NLRP3 inflammasome 
 
Inflammasomes are multimeric protein complexes that assemble in the cytosol 
after sensing PAMPs or DAMPs (Lamkanfi M et al, 2014; Martinon F et al, 2002). Activation 
of the inflammasome is a key function mediated by the innate immune system. The NOD-like 
receptor (NLR) protein pyrin domain containing 3 (NLRP3) inflammasome is the most 
extensively studied and it is formed after oligomerization of NLRP3 and subsequent 
recruitment of adaptor protein apoptosis-associated speck-like protein containing CARD 
(ASC) and pro-caspase-1 (Takeuchi O et al, 2010). Upon activation of NLRP3, ASC proteins 
assemble into fiber-like structures culminating in the production of a large protein aggregate 
that amplifies the activation of caspase-1 (Martinon F et al, 2002; Sutterwala FS et al, 2014). 
The NLRP3 inflammasome is activated in response to a variety of infectious stimuli or to 
cellular stress caused by various danger signals, including misfolded protein aggregates and 
aberrant accumulation of certain metabolites (Takeuchi O et al, 2010).  
Importantly, inflammasomes have been linked to several disorders, including 
neurodegenerative diseases. For instance, it was recently shown that Nlrp3 gene expression 
increases in the spinal cord during experimental autoimmune encephalomyelitis progression, 
an animal model that mimics MS. In contrast, Nlrp3-deficient mice present less severe 
disease, accompanied by a reduction in inflammatory cells infiltration and astrogliosis (Gris D 
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et al, 2010; Inoue M et al, 2012). Moreover, in AD, fibrillary Aβ induces NLRP3 
inflammasome-dependent activation of caspase-1, suggesting a link between inflammasome 
activation and AD (Halle et al, 2008). Similarly, also fibrillary α-syn fully activates the NLRP3 
inflammasome in PD by inducing caspase-1 activation and mature IL-1β production (Codolo 
G et al, 2013). 
 
Other proinflammatory mediators, apart from cytokines and inflammasomes, such 
as iNOS and cyclooxygenase-2 (COX2) are also involved in the inflammatory response 
mediated by activated microglia, being highly regulated by diverse adaptor molecules. 
 
3. Neurodegeneration and mechanisms of cell death 
Programmed cell death (PCD) include apoptosis and autophagic cell death and it 
is crucial for normal neural development. PCD regulates the number and types of cells in the 
developing brain and spinal cord, and plays a key role in constructing an efficient neuronal 
network (Miura M, 2011). Under pathological conditions, PCD is also responsible for the loss 
of neurons associated with neurodegenerative diseases (Tendi EA et al, 2010). 
Apoptosis is a form of regulated cell death executed by a group of intracellular 
cysteine proteases, namely caspases (Thornberry NA et al, 1998). This type of cell death 
occurs by two well-characterized pathways: the extrinsic pathway, which is activated through 
the binding of various death-inducing ligands to their respective receptors; and the intrinsic 
pathway that is activated after mitochondrial intermembrane space proteins are released into 
the cytosol (Du C et al, 2000; Peter ME et al, 2003). Ultimately, apoptosis leads to 
phosphatidylserine (PS) exposure on the cell surface, nuclear condensation, membrane 
blebbing and genomic DNA fragmentation (Elmore S, 2007). Importantly, this type of cell 
death is frequently implicated in neurodegeneration. For instance, studies in the brain of AD 
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patients showed a strong upregulation of apoptosis when compared to healthy age-matched 
controls, with activation of caspase-3 being detected in more than 50% of hippocampal 
neurons (Su JH et al, 2011; Colurso GL et al, 2003). Similarly, in PD, apoptosis is also 
considered the dominant mechanism for neurodegeneration (Kountouras J et al, 2012). 
Conversely, necrosis is characterized by a rapid loss of plasma membrane 
integrity, in addition to organelle swelling and ensuing inflammatory responses (Festjens N et 
al, 2006; Vandenabeele P et al, 2010). This type of cell death frequently occurs when cells 
are challenged with excessive external stress, such as heat, ischemia, and pathogen 
infection (Zhou W et al, 2014). For a long time, necrosis was considered as an accidental 
and passive cell death mechanism. Interestingly, the purely unregulated nature of necrosis 
was questioned in 1988, when some authors reported that distinct cell types died in response 
to the same trigger, TNF-α, while manifesting either the features of apoptosis or a 
morphology without nuclear disintegration (Laster SM et al, 1988). Since then, studies have 
reported that a subset of necrosis, known as necroptosis, may be a form of regulated cell 
death (Degterev A et al, 2005). Importantly, some studies have shown that necroptosis is 
involved in the pathogenesis of several diseases, including neuronal damage induced by 
ischemic insults, as well as Huntington’s disease (HD), ALS and MS (Vandenabeele P et al, 
2010).  
 
3.1. Necroptosis  
During a long time, apoptosis was considered the sole form of regulated cell 
death during development, homeostasis and disease, whereas necrosis was regarded as an 
unregulated and uncontrollable process. However, evidence now reveal that some subtypes 
of necrosis such as necroptosis can also be regulated (Vandenabeele P et al, 2010). 
14 
 
Necroptosis has been described as an alternative cell death pathway triggered by 
death receptor signaling in multiple cell types (Degterev A et al, 2005). In addition, it was 
already demonstrated that necroptosis involves not only the early loss of cytoplasmic 
membrane integrity and then a loss of mitochondrial membrane potential, but also the 
activation of autophagy, probably as a self-clearance mechanism (Degterev A et al, 2005; 
Holler N et al, 2000). Nevertheless, necroptotic cell death in vitro is confirmed by plasma 
membrane rupture and lack of specific apoptotic markers such as caspase activation, 
chromatin condensation or nucleosomal-sized DNA fragmentation. By flow cytometry, 
necrotic cells can be distinguished by the concomitant inclusion of fluorescent DNA dyes 
such as propidium iodide (PI) and positive Annexin V staining, whereas live cells and early 
apoptotic cells are impermeable to PI (Krysko DV et al, 2008). 
 
3.1.1. Necroptosis activation in vitro 
  
Necroptosis was first recognized in 1998 as a caspase-independent form of 
regulated cell death that can be triggered by treatment with TNF-α only in the presence of a 
pan-caspase inhibitor, such as Z-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) (Vercammem 
D et al, 1998). Since then, necroptosis has been intensively studied upon stimulation of 
death receptors, particularly tumor necrosis factor receptor 1 (TNFR1). However, some 
studies have shown that the death receptor cluster of differentiation (CD)95 and tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand receptor (TRAIL-R)1/R2 are also 
inducers of necroptosis (Fouqué A et al, 2014). Currently, it is known that necroptosis can be 
initiated not only by ligands of the death receptor family but also by a variety of extracellular 
and intracellular stimuli that induce their expression and/or activation (Upton JW et al, 2012). 
Throughout the years, several authors have reported that various cell types can be 
sensitized to death receptor-induced necroptosis by inhibition of caspases with 
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pharmacological compounds, such as zVAD-fmk. Indeed, the murine fibroblast-like cell line 
L929 undergo spontaneous or TNF-induced necroptosis after treatment with zVAD-fmk 
(Vercammen D et al, 1998). Later studies demonstrated that this necroptotic response is, at 
least in part, mediated via autocrine TNF-α secretion (Wu YT et al, 2011). Importantly, 
various cellular stimuli can also induce activation of the proinflammatory and cell death 
protective NF-κB that, when activated, might lead to the production and autocrine secretion 
of TNF-α, thus enabling autocrine TNF receptor (TNFR) stimulation. In addition, other reports 
have also shown that T cells are sensitized for TNF-induced, TRAIL-induced or CD95-
induced necroptosis by zVAD-fmk (Holler N et al, 2000).  
TLRs are key sensors of the innate immune system that can recognize 
endogenous DAMPs to activate inflammatory signaling. During TLR2, TLR3, TLR4, TLR5 or 
TLR9 stimulation, caspase-8 inhibition promotes necroptosis that is dependent on adaptor 
molecules such as myeloid differentiation primary response 88 (MyD88) in macrophages and 
other cell types (Kaiser WJ et al, 2013; Schworer SA et al, 2014). Importantly, signaling 
through MyD88 also induces autocrine secretion of TNF-α and further signaling via TNFR 
(Kaiser WJ et al, 2013). On the other hand, cellular inhibitor of apoptosis protein (cIAP)1/2 
antagonist, TLR3 agonists and IFN-γ may trigger necroptosis independently of death 
receptors (Feoktistova M et al, 2011; Kim SJ et al, 2013). 
Murine cytomegalovirus (MCMV) can also activate DNA-dependent activator of 
interferon regulatory factors (DAI), therefore inducing necroptosis (Upton JW et al, 2012), 
and finally, a number of cell-intrinsic stimuli, such as genotoxic stress may activate 

















Figure 3. Necroptosis activators. Many triggers of necroptosis have been identified and include 
death receptors TNFR, CD95, TRAIL, TNF-related weak induced of apoptosis (TWEAK), as well as 
genotoxic stress and PAMPs, such as LPS. Recently, IFNs were also shown to induce necroptosis 
(Berghe TV et al, 2014). 
 
3.1.2. Molecular mechanisms of necroptosis 
Although there is a large variety of necroptosis activators, the members of the 
TNFR superfamily, are still the major mediators of this type of cell death. At the molecular 
level, after TNFR triggering, receptor-interacting protein 1 (RIP1) ubiquitination controls the 
switching between pro-survival signaling, and apoptotic and/or necroptotic cell death. Briefly, 
after ligand binding to TNFR1, two complexes with opposing signaling can be formed. The 
pro-survival complex, also called complex I, contains the adaptor protein TNFR1-associated 
death domain protein (TRADD), RIP1, TNF-associated factor 2 (TRAF2), E3-ubiquitin ligases 
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cIAP-1, cIAP2, and hem-oxidized iron-regulatory protein 2 ubiquitin ligase-1 (HOIL-1) that, 
along with HOIL-1L interacting protein (HOIP) and SHANK-associated RH domain-interacting 
protein (SHARPIN), form the linear ubiquitin chain assembly complex (LUBAC) (Haas TL et 
al, 2009) (Figure 4). In complex I, RIP1 is rapidly modified by ubiquitination, which includes 
Met1-linear and Lys63-linked polyubiquitination mediated by E3 ligases LUBAC and cIAP1, 
respectively. Ubiquitination of RIP1 functions as a scaffold for the recruitment of NF-κB 
essential modulator (NEMO) and transforming growth factor beta-activated kinase 1 (TAK1), 
the critical mediators of NF-κB and MAPK pathways, respectively. In fact, RIP1 recruitment 
to complex I and its polyubiquitination by TRAF2/5, cIAP1 and cIAP2 promotes the activation 
of ERK, JNK and p38 signaling pathways, which leads to cell survival and inflammation 
(Mahoney DJ et al, 2008). Complex I remains associated with TNFR1 (Bertrand MJ et al, 
2008). Importantly, RIP1, but not its kinase activity, has an important role in the survival-
promoting activity mediated by complex I (Degterev A et al, 2005). By contrast, 
deubiquitination of RIP1 by cylindromatosis (CYLD), a Lys63-specific deubiquitinating 
enzyme, promotes apoptosis or necrosis through the formation of the cytoplasmic death-
inducing signaling complex termed complex II (Hitomi J et al, 2008) (Figure 4). Endosomal 
internalization of TNFR1 is accompanied by the release of the complex from TNFR1 and 
recruitment of caspase-8, FAS-associated death domain protein (FADD), TRADD, and 
cellular FLICE-like inhibitory protein (cFLIP), resulting in the formation of complex IIa. This 
complex can trigger apoptosis through activation of downstream caspase-3 and -7, by FADD 
and caspase-8, and inhibit necrosis by cleavage of RIP1, RIP3, and CYLD (O’Donnell MA et 
al, 2011). On the other hand, complex IIb initiates necroptosis. If recruitment of caspase-8 is 
prevented, RIP1 and RIP3 accumulate and become phosphorylated, leading to necroptosis 
(He S et al, 2009; Zhang DW et al, 2009) (Figure 4). RIP1 and RIP3 kinases contain small 
protein domains called rip homotypic interaction motifs (RHIMs), by which they interact. 
Indeed, active RIP1 can move into alternative protein complexes, where it can activate RIP3 
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via RHIM-RHIM interactions, leading to necroptosis (Sun X et al, 2002). More recently, it was 
demonstrated that interaction between RIP1 and RIP3 forms a large amyloid-like structure, 
named necrosome, which is a key event in the necroptotic signaling pathway (Li J et al, 
2012). The physical interaction between both proteins allows for their auto- and trans-
phosphorylation, which is important for proper necrosome activity (Li J et al, 2012; Ofengeim 
D et al, 2013). What determines the switch from complex IIa to IIb is still unclear.  
Although less explored, necroptosis can also be initiated by members of the PRR 
family, including TLR that are expressed by cells of the innate immune system, such as 
microglia cells in the CNS, as previously described. The TLR-activated microglia undergo 
downstream Toll-IL-1 receptor domain-containing adapter-inducing interferon-β (TRIF) 
activation, leading to RIP3-dependent necroptosis, when exposed to caspase inhibitors 
(Fricker M et al, 2013). Indeed, after TLR3/TLR4 stimulation in combination with caspase 
inhibition, TRIF, which is an adaptor-signaling molecule for receptors possessing a RHIM 





Figure 4. RIP1-mediated multimodal signaling events downstream of TNFR1. Upon binding to 
TNF-α, the cytoplasmic death domain of trimerized TNFR1 recruits a membrane-associated complex, 
named complex I, which comprises TRADD, RIP1, TRAF2, cIAP1, cIAP2 and the complex LUBAC. In 
complex I, RIP1 is polyubiquitinated, which mediates the recruitment and activation of TAK1 and 
inhibitor of κB (IκB) kinase (IKK) complex by ubiquitin binding. The phosphorylation and ubiquitin 
proteasome system-mediated degradation of IκB leads to activation of NF-κB. In contrast, alternative 
cytosolic complexes, complex IIa or complex IIb can also be formed. Complex IIa includes the adaptor 
protein FADD, caspase-8 and RIP1 and mediates the activation of caspase-8 and consequently 
apoptosis. When the activation of caspase-8 is inhibited, RIP1 kinase is activated and binds to RIP3 to 




More recently, mixed lineage kinase like (MLKL) has been reported as a key 
player in the necroptotic process. It appears that necrosome assembly leads to recruitment 
of MLKL (Conrad M et al, 2016). MLKL consists on a carboxy-terminal pseudokinase domain 
that is connected to an amino-terminal four-helix bundle (4HB) domain by a two-helix linker. 
This 4HB domain is the cell death executioner domain that is kept in an inactive state by the 
pseudokinase domain. Moreover, MLKL is phosphorylated by RIP3 at Thr357 and Ser358 
that are located in the pseudokinase domain, thus allowing MLKL oligomerization and 
migration to the plasma membrane (Cai Z et al, 2014; Chen X et al, 2014; Hildebrand JM et 
al, 2014). The precise mechanism by which MLKL induces membrane rupture is 
controversial, with some reports implicating disruption of calcium or sodium ion channels (Cai 
Z et al, 2014; Chen X et al, 2014), and others showing direct binding to membrane 
phospholipids and disruption of membrane integrity (Dondelinger Y et al, 2014).  
Importantly, under specific cellular contexts, increased levels of RIP3 or 
overexpression of a RIP3 phospho-mimetic mutant can trigger necroptosis in the absence of 
RIP1, suggesting RIP3 as the master regulator of necroptotic cell fate (Moujalled DM et al, 
2013; Upton JW et al, 2010; Zhang DW et al, 2009). 
Finally, the mitochondrial protein phosphoglycerate mutase family member 5 
(PGAM5) was also suggested to interact with necrosome components. In fact, this protein 
was initially thought to recruit RIP1/RIP3 to the mitochondria to induce cell necroptosis 
(Wang Z et al, 2012). However, now it is known that the influence of PGAM5 on RIP1/RIP3 
recruitment is very low. Moreover, PGAM5 appear to have a necroptosis protective function, 
both in vitro and in vivo, possibly due to its ability to promote PTEN-induced putative kinase 1 
(PINK1)-dependent mitophagy of damaged mitochondria (Lu W et al, 2016). In addition, 
overproduction of ROS has also been described as a possible contributing factor in some 
cellular contexts (Degterev A et al, 2005; Zhang DW et al, 2009). Indeed, RIP3 can activate 
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multiple metabolic enzymes, thus increasing energy metabolism-associated ROS production 
(Zhang DW et al, 2009). 
 
3.1.3. Necroptosis and inflammation 
Necrosis is generally considered a proinflammatory type of cell death when 
compared to apoptosis. During necrosis, the intracellular constituents, or DAMPs, are 
released to the extracellular space where innate immune cells such as macrophages are 
located, thus promoting inflammation (Moriwaki K et al, 2013). Necroptosis, similar to 
necrosis, is also thought to result in the release of DAMPs into the extracellular space, 
including molecules with cytokine-like properties such as IL-1, ATP, high-mobility group 
protein B1 (HMGB1) and heat shock proteins, thus implicating necroptosis as a highly 
inflammatory type of cell death (Davidovich P et al, 2014) (Figure 5). 
The effect of necroptotic cell death in inflammation is now a topic of strong 
research. For instance, studies using mice with epidermis-specific FADD deletion 
demonstrated that these animals presented spontaneous necroptosis of keratinocytes and 
developed severe inflammatory skin disease. The development of this inflammatory 
phenotype was dependent on RIP3-mediated necroptosis, since RIP3 deficiency fully 
prevented keratinocyte necroptosis and skin inflammation (Bonnet MC et al, 2011). Other 
studies reported that mice with epidermal keratinocyte restricted caspase-8 ablation 
developed severe inflammation, suggesting that caspase-8 deficiency triggered inflammation 
by a mechanism that involves p38-dependent upregulation of pro-caspase-1, resulting in 
inflammasome-mediated release of IL-1β (Kovalenko A et al, 2009). Interestingly, TLR4 
signaling pathway appears to be involved in HMGB1 secretion from macrophages by a 
mechanism dependent on IL-1R-associated kinase 4 (IRAK4), indicating that HMGB1 might 
be released during TLR4-mediated necroptosis (Wang et al, 2010). Additionally, it has also 
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been proposed that TLR signaling contributes to the severe inflammatory response in 
ischemia-reperfusion injury models, indicating that, in this case, inflammation may be 
induced by DAMPs released by necroptotic cells (Wu et al, 2010). 
 
Figure 5. Necroptotic cells release proinflammatory mediators. Membrane rupture, an initial step 
of necroptosis, leads to the release of intracellular DAMPs to the extracellular space where innate 
immune cells are located, thus activating them to elicit a secondary inflammatory response. This 
inflammatory response is dependent on MyD88 and NF-κB signaling: HMGB1 via TLR4 and RAGE; 
IL-1 and IL-33 via IL-1R. For instance, HMGB1-TLR4 can be internalized into the endosome to initiate 
two different TRIF-dependent pathways: the first, a RIP1-dependent pathway, leading to NF-κB-
induced proinflammatory cytokine production; and the second that involves the induction of interferon 
regulatory transcription factors (IRFs) and production of IFN-β. In addition, TNF-α triggers NF-κB 
signaling that is regulated by RIP1. Loss of cIAPs can lead to TNF- α-induced phosphorylation of RIP3 
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or activation of caspase-8. Phosphorylation of RIP3 can promote formation of the NLRP3 
inflammasome, which activates caspase-1 generating mature IL-1β, or proinflammatory cytokine 
production (Silke J et al, 2015). 
 
The role of RIP1 and RIP3 in animal models of human diseases has been highly 
associated with necroptosis. However, accumulating evidence indicates that RIP1 
ubiquitination, deubiquitination and phosphorylation are the key events that determine 
whether a cell survive and activate an inflammatory response, or die through apoptosis or 
necroptosis (Christofferson DE et al, 2010; O’Donnell MA et al, 2011). In this regard, RIP1 
was shown to have an important role in modulating NF-κB activation (Ting AT et al, 1996). 
Further, RIP1 was also implicated in TLR-mediated inflammation. After TLR3 and TLR4 
activation, RIP1 modulates the downstream intracellular response, which involves two 
parallel pathways mediated by MyD88 and TRIF (Cusson-Hermance N et al, 2005; Meylan E 
et al, 2004) (Figure 5).  
Other studies have shown that RIP1 kinase has an important role in regulating 
the inflammatory response in primary cell types such as macrophages and dendritic cells. In 
dendritic cells, deletion of caspase-8 results in increased production of proinflammatory 
cytokines TNF-α, IL-1β, IL-6, and IL-12, which is facilitated by RIP1 kinase activity (Moriwaki 
K et al, 2014), suggesting that caspase-8 is an important suppressor of the inflammatory 
response. Also, macrophages lacking cIAP1, cIAP2 and X-linked IAP (XIAP) secreted 
elevated levels of cytokines and chemokines, such as TNF-α and IL-6, which involves a 
mechanism that depends on RIP1 and RIP3, but not MLKL (Wong WW et al, 2014). 
Importantly, RIP1 knock-out mice die at birth due to severe systemic inflammation, whereas 
knock-in of RIP1 kinase-dead are viable and healthy, indicating that RIP1 has indeed a third 
function beyond its NF-κB-inducing activation and kinase function in necroptosis (Berger SB 
et al, 2014; Kaiser WJ et al, 2014).  
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Recently, it was also reported that RIP1 and RIP3 can regulate the 
inflammasome activation. In fact, caspase-8 deficiency in dendritic cells enhanced TLR4-
induced formation and activation of the NLRP3 inflammasome by a mechanism dependent 
on RIP1, RIP3, MLKL and PGAM5, thus resulting in increased expression of mature IL-1β. 
Interestingly, these effects appear to be independent of necroptosis (Vince JE et al, 2012). 
Similarly, in IAP-competent cells, caspase-8 attenuates the assembly and function of NLRP3 
inflammasome primed by TLR4 or TLR2 engagement, and the consequent IL-1β production 
is largely dependent on both RIP1 kinase activity and RIP3 (Kang TB et al, 2013). 
 
3.1.4. Necroptosis in disease 
The physiological relevance of necroptosis has been demonstrated in a variety of 
paradigms. In particular, necroptosis appears as a critical event in the pathogenesis of 
several inflammatory diseases, including neurodegenerative diseases. Indeed, increased 
expression of RIP1 and RIP3, two critical necroptosis mediators, is observed in many 
pathological conditions (Roychowdhury S et al, 2013; Vitner EB et al, 2014). 
Necroptosis is involved in the pathogenesis of pancreatitis (He S et al, 2009), 
chronic inflammation of gut (Gunther C et al, 2011; Welz PS et al, 2011), skin inflammation 
(Bonnet MC et al, 2011), as well as lung (Rodrigue-Gervais IG et al, 2014), kidney (Tristão 
VR et al, 2012), heart (Smith CC et al, 2007), liver (Afonso MB et al, 2015; Takemoto K et al, 
2014) and hematopoietic system injuries (Roderick JE et al, 2014). Importantly, in all cases, 
necroptosis inhibition resulted in disease improvement. 
Regarding the CNS, other studies reported that necroptosis plays a critical role in 
the pathogenesis of cell death during traumatic brain injury, ischemic stroke, and neonatal 
hypoxia-ischemia brain injury. The link between necroptosis and neuronal damage has been 
suggested by studies demonstrating a protective effect of necroptosis inhibition in these 
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diseases. Indeed, in traumatic brain injury, mice administered with RIP1 kinase inhibitor 
necrostatin-1 (Nec-1) had reduced brain damage and improved motor and cognitive 
performance. In addition, Nec-1 also reduced brain neutrophil infiltration and suppressed 
microglial activation (You Z et al, 2008). Similarly, in a mouse model of transient focal 
cerebral ischemia, Nec-1 markedly decreased the infarct volume (Degterev A et al, 2005). 
Moreover, Nec-1 blocked RIP1/RIP3 interaction in neurons of a mouse model of ischemia 
brain injury. Importantly, necroptosis inhibition by Nec-1 also suppressed IL-1β, IL-6 and 
TNF-α expression, and NF-κB activation, thus highlighting the relevance of necroptosis 
inhibition to attenuate neuroinflammation (Northington FJ et al, 2011). 
Inhibition of RIP1 kinase activity by Nec-1 was also protective against 
excitotoxicity in a primary rat cortical culture (Li Y et al, 2008) and in a mouse hippocampal 
cell line (Xu X et al, 2007). In addition, RIP3 deficiency alleviated the loss of mouse 
hippocampal neurons after stimulation with TNF-α (Liu S et al, 2014), as well as the onset 
and progression of disease in a transgenic mouse model of HD (Vandenabeele P et al, 2010; 
Zhu S et al, 2011), suggesting that necroptosis inhibition may have a beneficial effect in 
these conditions. Studies using co-cultures of primary motor neurons with astrocytes showed 
that astrocytes compromise neuronal survival in a RIP1 kinase- and MLKL-dependent 
manner. Importantly, Nec-1 rescues the death of motor neurons, indicating RIP1 inhibition as 
an important therapeutic strategy in ALS therapeutics (Re DB et al, 2014).  
The contribution of necroptosis to neurodegeneration has been recently 
questioned by several authors that interpret microglia necroptosis as a strategy for 
preserving neurons. More specifically, it was shown that caspase-8 inhibition in mixed 
cerebellar cultures of primary neurons, astrocytes, and microglia prevented LPS-induced 
neuronal loss (Fricker M et al, 2013). 
The contribution of necroptosis to inflammation is currently the focus of much 
attention. Of particular importance, caspase-8 is predominantly expressed in the microglial 
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lineage and defects in its activation have been associated with inflammation by engaging the 
necroptotic machinery (Wallach D et al, 2014). In this respect, a recent study showed 
elevated levels of inactive caspase-8 in MS patients, suggesting that a defect in caspase-8 
activity in microglia in MS cortical lesions may activate necroptosis and promote inflammation 
(Ofengeim D et al, 2015). The same authors demonstrated that RIP1 and RIP3 were present 
at higher levels in an amyloid-like conformation in microglia, thus confirming necroptosis 
activation. Importantly, microglia necroptosis appears to promote inflammation through the 
release of TNF-α, which in turn further activates necroptosis in oligodendrocytes, thus 
contributing to disease progression (Ofengeim D et al, 2015).  
 
3.1.5. Targeting necroptosis  
 
RIP1 inhibitors 
In 2005, a phenotypic screen for small molecules that inhibit TNF-induced 
necrotic cell death in human monocytic U937 cells identified the first RIP1 kinase inhibitor, 
Nec-1, which is an allosteric inhibitor of RIP1, stabilizing a specific inactive conformation of 
the kinase domain (Degterev A et al, 2008; Takahashi N et al, 2012). Nec-1 has increased 
specificity for RIP1, while it has no effect on RIP2 and RIP3, two RIP proteins with 33% 
sequence identity in the kinase domain. Therefore, Nec-1 is considered a potent necroptosis 
inhibitor (Degterev A et al, 2008). However, this molecule is a far-from-ideal drug, having a 
very short in vivo half-life and non-specific activity against indoleamine 2,3-dioxygenase 
(IDO), an enzyme also involved in the inflammatory response (Vandenabeele P et al, 2013). 
Importantly, it has been shown that Nec-1 protected mice and rats against 
neurodegenerative conditions, such as AD, HD, and stroke, as well as retinal degeneration 
and inflammatory diseases (Degterev A et al, 2005; Degterev A et al, 2008; Jouan-Lanhouet 
S et al, 2014). Other studies have also demonstrated that Nec-1 analog, Nec-1 stable (Nec-
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1s), is > 1000-fold more selective than Nec-1, in addition to increased potency as necroptosis 
inhibitor (Degterev A et al, 2005; You Z et al, 2008). This molecule can prevent against TNF-
induced lethality in a mouse model of systemic inflammatory response syndrome (SIRS) 
(Northington FJ et al, 2011). By contrast, Nec-1 inactive (Nec-1i) showed to be 100x less 
effective than Nec-1 and 10x less potent than Nec-1 and Nec-1s, and it is often used as an 
inactive control in studies using Nec-1 to exclude nonspecific off-target effects inherent to 
inhibitors. Recently, also the anti-leukemic agents and breakpoint cluster region-abelson 
leukemia (BCR-ABL) inhibitors ponatinib and pazopanib were indicated as inhibitors of both 
RIP1 and RIP3 proteins (Fauster A et al, 2015; Najjar M et al, 2015). Indeed, ponatinib and 
pazopanib inhibit RIP1- and RIP3-dependent cell death as well as transcription of TNF-α, 
thus indicating their cytoprotective and anti-inflammatory properties (Fauster A et al, 2015). 
Furthermore, fusion of the scaffold of ponatinib and Nec-1s generated a hybrid molecule, 
named PN10, a highly potent and selective RIP1 inhibitor, which are able to protect against 
TNF-induced SIRS in vivo (Najjar M et al, 2015). 
 
RIP3 inhibitors  
Among the years, the recognition that necroptosis could be activated 
independently of RIP1 and the observation that RIP3 knockout mice are viable led to the 
development of RIP3 inhibitors. Mandal et al. have shown that three selective small 
compounds GSK’840, GSK’843 and GSK’872 are able to inhibit RIP3-dependent necroptosis 
with high specificity by interacting with RIP3 to activate caspase-8 (Mandal P et al, 2014). 
Importantly, these compounds are able to prevent LPS-induced death of mouse 
macrophages, as well as cell death induced by TNF-α plus zVAD-fmk and poly(I:C)-triggered 
death of interferon-β-sensitized cells in vitro. However, these RIP3 kinase inhibitors have an 





The first compound reported to inhibit MLKL was necrosulfonamide (NSA). This 
compound was used as a probe to identify MLKL as a downstream target of RIP3. This was 
confirmed by a study where NSA does not affect RIP3-dependent phosphorylation of MLKL. 
Later studies revealed that NSA can effectively block necroptosis induced by TNF-α plus 
zVAD-fmk in fibroblasts though interacting with MLKL (Sun L et al, 2012). However, NSA 
only acts on human MLKL and cannot be used to study necroptosis in mouse models. In 
addition, also a new class of MLKL inhibitors based on “compound 1” (GW806742X or SYN-
1215) was developed and recently described to target the pseudokinase domain of MLKL. 
However, compound 1 also binds to RIP1 and inhibits its kinase activity, thus failing at 
implicating MLKL in necroptosis, due to its lack of specificity (J Silke, personal 
communication). 
 Despite of the efforts made so far, no inhibitors of necroptosis are available for 
clinical use. Therefore, the development of new molecules that potentially modulate this type 















Here, we propose a new in vitro model to study necroptosis based on the murine 
BV2 microglial cell line. We aimed at identifying new inhibitors of necroptosis and further 
explore the signaling pathways involved. Additionally, we will also investigate if modulation of 
this type of cell death contributes to attenuate neuroinflammation, highlighting the potential 
use of necroptosis inhibitors to treat neurodegenerative diseases.  
The main objectives of this study were to: 
1. Implement a robust model to evaluate microglia necroptosis in vitro; 
2. Screen a library of forty-one newly synthetized small molecules that potentially 
inhibit necroptosis; 
3. Identify a lead molecule and characterize its in vitro activity;  
4. Explore the signaling pathways involved in lead activity, namely necroptosis 









































































































Lipopolysaccharide (LPS) from Escherichia coli 055:B5, necrostatin-1 (Nec-1) 
and dimethyl sulfoxide (DMSO) were from Sigma-Aldrich (St. Louis, MO, USA). Z-Val-Ala-
Asp-fluoromethylketone (zVAD-fmk) pan caspase inhibitor was from Enzo Life Sciences 
(Farmingdale, NY, USA). Two libraries of twenty small molecules potentially inhibitors of 
necroptosis were obtained through a collaboration with Professor Carlos Afonso, from the 
Bioorganic Chemistry group within iMed.ULisboa. 
 
2. Cell culture 
The murine BV2 cell line was cultured in Roswell Park Memorial Institute 1640 
(RPMI) medium (GIBCO® Life Technologies, Inc.; Grand Island, USA), supplemented with 
10% fetal bovine serum (FBS), 1% penicillin/streptomycin (GIBCO) and 1% GlutaMAXTM 
(GIBCO). Cells were maintained at 37°C in a humidified atmosphere of 5% CO2.  
Throughout the experiments, the culture media was replaced by a 
supplemented mixture without FBS, composed of RPMI, 1% penicillin/streptomycin, 1% 
insulin, transferrin, selenium and fibronectin (ITSF) (GIBCO), and 1 mg/mL bovine serum 
albumin (BSA) (GIBCO), next refered to as RPMI/ITSF.   
 
3. Cell treatment  
3.1. Optimization of an in vitro model of microglia necroptosis 
BV2 cells were plated in 96-well plates at 1x104 cells/well. Twenty-four hours 
after cell plating, media was removed and replaced with fresh RPMI/ITSF containing 100 
ng/mL LPS for additional 24 h. After that, cells were pre-treated with 30 µM Nec-1 for 1 h, 
followed by 25 µM zVAD-fmk for additional 24 h. BV2 cells without any treatment were used 
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as control. Cell viability and cell death were analyzed by standard methods as detailed 
below. 
3.2. Screening of small molecules for necroptosis inhibition  
BV2 cells were plated in 96-well plates at 7x103 cells/well. Twenty-four hours 
after cell plating, media was removed and replaced with fresh RPMI/ITSF containing 30 µM 
of each compound in test, 25 µM zVAD-fmk, zVAD-fmk plus 30 µM Nec-1 or compound for 
additional 24 h. BV2 cells without any treatment were used as control. Cell viability and cell 
death were analyzed by standard methods as detailed below. 
3.3. EC50 determination 
To determine the dose-response curve and EC50 value of the lead compound, 
BV2 cells were plated in 96-well plates at 7x103 cells/well. Twenty-four hours after cell 
plating, media was removed and replaced with fresh RPMI/ITSF containing Oxa12 at 
different concentrations (0.1, 0.5, 1, 2.5, 5, 10, 30 and 50 µM) plus 25 µM zVAD-fmk. 
Following 24 h of compound exposure, cell viability was evaluated using standard methods 
as detailed below. The EC50 value was determined with GraphPad Prism v.5.00 (GraphPad 
Software, San Diego, CA, USA) using the log (inhibitor) versus response function. To 
determine Oxa12-associated toxicity, the same procedure was used but with a different 
range of concentrations (1, 2.5, 5, 10, 30, 50, 100 and 150 µM) without zVAD-fmk. In all 
cases, DMSO was used as control. 
 
4. Evaluation of cell death and viability  
Cell viability was measured using the CellTiter 96® Aqueous Non-Radioactive 
Cell Proliferation Assay (Promega, Madison, WI, USA), according to the manufacturer’s 
35 
 
instructions. This homogenous, colorimetric method determines the number of viable cells in 
cytotoxicity assays. The assay is composed of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and an electron coupling 
reagent phenazine methosulfate (PMS). MTS is bioreduced by cells into a formazan product 
that can be measured spectrophotometrically at 490 nm in a plate reader. The conversion of 
MTS into the formazan product is accomplished by dehydrogenase enzymes found in 
metabolically active cells, and is directly proportional to the number of viable cells in culture. 
In brief, cell culture supernatants were replaced by 100 µL of MTS/PMS (19:1) solution 
prepared in fresh RPMI/ITSF, and cells incubated at 37°C for 30 min. Changes in 
absorbance were measured at 490 nm using GloMax® Multi Detection System (Sunnyvale, 
CA, USA).  
General cell death was evaluated using the lactate dehydrogenase (LDH) 
Cytotoxicity Detection KitPLUS (Roche Diagnostics GmbH, Manheim, Germany), according to 
the manufacturer’s instructions. The LDH assay measures membrane integrity as a function 
of the amount of cytoplasmic LDH released into the medium that can be quantified by a 
coupled enzymatic reaction. In the first step, LDH catalyzes the conversion of lactate to 
pyruvate via reduction of NAD+ to NADH. In the second step, diaphorase uses NADH to 
reduce a tetrazolium salt (INT) to a red formazan product. Thus, the level of formazan is 
directly proportional to the amount of LDH released, which is indicative of cytotoxicity. Hence, 
50 µL of supernatant from treated cells was transferred into a new 96-well plate and then 
incubated with 50 µL of assay substrate for 10 to 30 min, at room temperature, protected 
from light. Absorbance readings were measured at 490 nm, with 620 nm reference 





5. Evaluation of necroptosis signaling pathways 
BV2 cells were plated in 6-well plates at 4x105 cells/plate. Twenty-four hours after 
cell plating, media was removed and replaced with fresh RPMI/ITSF containing 100 ng/mL 
LPS for additional 24 h. After that, cells were pre-treated with 30 µM Nec-1 for 1 h, followed 
by 25 µM zVAD-fmk for additional 5 h. To evaluate Oxa12 potential in modulating 
necroptosis, cells were treated with zVAD-fmk, zVAD-fmk plus Nec-1, or zVAD-fmk plus 
Oxa12 for 24 h. BV2 cells without any treatment were used as control. 
5.1. Total protein extraction 
For total protein isolation, adherent cells were collected directly in nonyl 
phenoxypolyethoxylethanol (NP-40) lysis buffer (1% NP-40, 20 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 5 mM EDTA, 10% Glycerol, 1 mM dithiothreitol (DTT), and 1X proteases and 
phosphatases inhibitors), followed by sonication and centrifugation at 3200 g during 10 min 
at 4°C. Total protein extracts were recovered and stored at - 80 ºC. 
Protein concentration was determined by the colorimetric Bradford method using 
the Bio-Rad Protein Assay reagent (Bio-Rad), according to the manufacturer’s instructions. 
BSA (Sigma-Aldrich) was used as standard, and absorbance measurements were performed 
at 595 nm using Model 680 microplate reader (Bio-Rad). Protein concentrations were 
interpolated from the BSA standard curve.   
5.2. Soluble and insoluble fractions 
Necrosome formation was evaluated by the enrichment of necroptosis mediators 
in the insoluble proteome of BV2 cells. Adherent cells were collected in phosphate-buffered 
saline/ethylenediaminetetraacetic acid (PSB/EDTA), centrifuged at 600 g for 5 min at 4°C, 
and the pellet homogenized in NP-40 lysis buffer. Whole-cell lysates were then rotated for 30 
min at 4°C, followed by centrifugation at 16000 g for 20 min at 4°C. Supernatants were 
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removed and used as the soluble fraction. To remove carryovers, the pellet was washed with 
NP-40 lysis buffer and further centrifuged at 16000 g for 10 min at 4°C. Then, the pellet was 
resuspended in urea-SDS buffer (8 M urea, 3% sodium dodecyl sulfate (SDS) in NP-40 lysis 
buffer) followed by sonication. Lysates were spun again at 16000 g for 20 min at 4°C, and 
the supernatant removed and used as the insoluble fraction. Protein concentration was 
determined using the bicinchoninic acid (BCA; Thermo Fisher Scientific, Inc.) assay for 
soluble and insoluble fractions, according to the manufacturer’s recommendations. 
5.3. Western blot analysis and densitometric analysis 
Steady-state protein production was determined by Western blot analysis. Briefly, 
40-50 µg of total protein extracts and 20 µg of soluble and insoluble protein fractions were 
denatured, electrophoretically resolved on 8% SDS-polyacrylamide gels, and transferred 
onto nitrocellulose membranes. Uniform protein loading and transfer was confirmed by 
transient staining with 0.2% Ponceau S (Merck, Darmstadt, Germany). Next, nonspecific 
binding sites were blocked with a 5% milk solution in Tris-buffered saline (TBS) for 1 h. 
Membranes were then incubated overnight at 4°C with primary rabbit antibodies reactive to 
RIP1, RIP3, Akt, p-Akt  (Ser473) and NF-κB p65 (#7881; #135170; #8312; #7985; #372 from 
Santa Cruz Biotechnology; CA, USA), MLKL (#M6697; Sigma Aldrich), p-MLKL (Ser358) and 
p-NF-κB p65 (Ser536)  (#196436; #131109 from Abcam; Cambridge, UK), p-p38 
(Thr180/Tyr182) (#9211 from Cell Signaling; MA, USA); and with primary mouse monoclonal 
antibodies reactive to JNK, p-JNK (Thr183/Tyr185),  p38α/β and IκBα (#7345; #6254; #7972; 
#371 from Santa Cruz Biotechnology) and p-IκBα (Ser32/36) (#9246 from Cell Signaling). 
Membranes were then washed three times with TBS containing 0.2% Tween 20 (TBS-T), 
and incubated with anti-rabbit or anti-mouse secondary antibodies conjugated with 
horseradish peroxidase (Bio-Rad) for 2 h at room temperature. After rinsing three times with 
TBS-T, the immunoreactive complexes were visualized by chemiluminescence with 
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ImmobilonTM Western (Milipore) or SuperSignal West Femto substrate (Thermo Fisher 
Scientific, Inc.). β-actin (AC-15; Sigma-Aldrich) was used as loading control. Densitometric 
analysis was performed with the Image Lab software Version 5.1 Beta (Bio-Rad).  
 
6. Evaluation of inflammatory mediators 
 
To evaluate transcript levels and secretion of inflammatory mediators, BV2 cells 
were plated in 12-well plates at 8x105 cells/well. Twenty-four hours after cell plating, media 
was removed and replaced with fresh RPMI/ITSF containing 25 µM zVAD-fmk, 30 µM Nec-1, 
30 µM Oxa12, or no addition, and zVAD-fmk plus Nec-1 or Oxa12 for additional 24 h. 
Adherent cells were used for total RNA extraction and qRT-PCR analysis, while cell culture 
media was used for ELISA. 
 
6.1. Total RNA extraction and quantitative Real-Time PCR 
Total RNA was extracted from BV2 cells with TRIzolTM reagent (Invitrogen, Grand 
Island, USA), according to the manufacturer’s protocol. RNA was quantified using a QubitTM 
2.0 fluorometer (Invitrogen).  
Real-time PCR (RT-PCR) was performed to determine the expression level of 
COX2, IL-1β, IL-6, NLRP3 and TNF-α. Reverse Transcription reactions were performed 
using total RNA and NZY Reverse Transcriptase (NZYTech, Lisbon, Portugal), according to 
the manufacturer’s instructions. RT-PCR reactions were performed using specific primers 
and SYBR Green PCR master mix (Thermo Fisher Scientific, Inc.). Triplicate reactions were 
run per sample using a 7300 Real-Time PCR System, and data was acquired and analyzed 
using 7000 System sequence Detection Software, version 1.2.3 (Applied Biosystems, 
Thermo Fisher Scientific, Inc.). The relative amounts of each gene were calculated based on 
the standard curve normalized to the level of hypoxanthine-guanine 
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phosphoribosyltransferase (HPRT) and expressed as fold-change from control cells. Primer 
sequences are presented in Table 1. 
 
Table 1. Primer sequences used to amplify indicated cDNAs. 
Primer Forward (5’-3’) Reverse (5’-3’) 
COX2 CAGCCAGGCAGCAAATCCTT AGTCCGGGTACAGTCACACT 
 
HPRT GGTGAAAAGGACCTCTCGAAGTG ATAGTCAAGGGCATATCCAACAACA 
IL-1β TGCCACCTTTTGACAGTGATG TGATGTGCTGCTGCGAGATT 
IL-6 GACGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA 
NLRP3 AGAGCCTACAGTTGGGTGAAATG CCACGCCTACCAGGAAATCTC 
TNF-α AGGCACTCCCCCAAAAGATG TGAGGGTCTGGGCCATAGAA 
 
6.2. Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Sandwich ELISA kits (PeproTech, London, UK) were used to determine TNF-α 
concentration in BV2-treated cells culture media. The kit contains 96-well plates that were 
coated with a capture antibody specific for TNF-α overnight at room temperature. The next 
day, the liquid was removed and wells washed 4x with washing buffer (0.05% Tween-20 in 
PBS). Blockage of non-specific binding was performed by adding blocking buffer (1% BSA in 
PBS) for 1 h at room temperature, followed by the same cycle of washes. At this point, 100 
µL of BV2 cell supernatants were added to each well and incubated for 2 h at room 
temperature. 4 washes were performed as before. The detection antibody was then added to 
each well and incubated for 2 h at room temperature, followed by 4 washes as before. 
Finally, avidin peroxidase was added and incubated during 30 min at room temperature, 
followed by 4 washes as before. This step allows the linking of peroxidase over a 
strepdavidin-biotin bridge to the antibody-TNF-α-antibody sandwich structure. Conversion of 
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the colorless substrate into a soluble colored product was achieved by adding peroxidase 
substrate solution, which is enzymatically processed into a blue colored product. Color 
intensity is proportional to the quantity of TNF-α contained in each sandwich structure. 
Therefore, samples were incubated at room temperature until the development of blue color 
was visually detectable (± 30 min), and then absorbance was read at 450 nm, with 590 nm 
reference wavelength using a Bio-Rad Model 680 microplate reader. TNF-α concentration 
(pg/mL) was calculated from standard curves. 
 
7. Microscopy  
 
BV2 cells morphology was evaluated by phase-contrast microscopy using a 
Primo Vert microscope (Carl Zeiss MicroImaging GmbH, Gottingen, Germany). Images were 
acquired under 100x magnification using an AxioCam 105 Color camera with the ZEN lite 
2012 (both from Carl Zeiss MicroImaging GmbH).  
 
8. Statistical analysis 
 
All data are presented as mean ± standard error of the mean (SEM) of at least 
three independent experiments. Comparison between groups was made by one-way 
analysis of variance (ANOVA) followed by post hoc Bonferroni’s test. Analyses and graphical 
presentation were performed with the GraphPad Prism software version 5 (GraphPad 

























































zVAD-fmk induces necroptosis in BV2 microglia cells 
Recent studies have demonstrated that primary microglia undergo RIP1/RIP3-
dependent necroptosis after treatment with LPS or TLR ligands, when caspases are inhibited 
(Fricker M et al, 2013; Kim SJ et al, 2013). Importantly, other studies also showed that 
treatment with the pan caspase inhibitor zVAD-fmk alone induces necroptosis in L929 cells, 
by a mechanism that depends on autocrine production of TNF-α (Christofferson DE et al, 
2012; Wu YT et al, 2011). In the present study, we propose a new in vitro model for the study 
of microglia necroptosis, based on the murine BV2 microglial cell line. We evaluated 
necroptosis activation after 24 h treatment with LPS, a well-known TLR4 agonist, followed by 
incubation with the pan caspase inhibitor, zVAD-fmk, for additional 24 h. Importantly, we also 
determined if zVAD-fmk alone was capable of inducing necroptosis in BV2 cells.  
As depicted in Figure 6, high levels of cell death were detected in BV2 cells after 
treatment with zVAD-fmk alone, as evaluated by MTS metabolism and LDH activity assays 
(p ˂ 0.001). Incubation with LPS prior to zVAD-fmk further decreased BV2 cells viability in 
approximately 30%, as revealed by MTS (p ˂ 0.001). Importantly, addition of Nec-1, a RIP1-
specific kinase inhibitor, fully reverted cell death to control levels in all conditions tested (p ˂ 
0.001), thus implicating RIP1-dependent necroptosis as the death mechanism (Fig. 6). These 
results indicate that zVAD-fmk alone is capable of inducing necroptosis in BV2 cells. 
However, co-incubation with LPS appears to potentiate or accelerate the cell death 
mechanism, suggesting the involvement of necroptosis in an inflammatory context. 
Others have also reported that primary microglia treated with LPS after caspase 
inhibition show an increase in RIP1 and RIP3 total protein levels, the major effectors of 
necroptosis (Fricker M et al, 2013). We confirmed these results as BV2 treated with LPS for 
24h presented increased RIP1 and RIP3 total protein levels, suggesting that LPS 
predisposed cells to necroptosis induction (Fig. 7). As expected, LPS/zVAD-fmk co-
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incubation further increased RIP1 and RIP3 total levels when compared to LPS alone, 
indicating necroptosis activation in these conditions. This is in accordance with MTS/LDH 
data.  
Surprisingly, Nec-1 treatment induced a marked increase of RIP1 and RIP3 total 
protein levels (Fig. 7). Therefore, we decided to investigate the accumulation of both proteins 
in the insoluble proteome, as necroptosis activation requires the assembly of a detergent 










Figure 6. BV2 microglial cells undergo necroptosis when exposed to LPS/zVAD-fmk or zVAD-
fmk alone. BV2 cells were pre-treated with 100 ng/mL LPS for 24 h and then exposed to the pan-
caspase inhibitor zVAD-fmk (25 µM) for additional 24 h. Cell metabolic activity was determined by 
MTS metabolism and cell membrane integrity by LDH activity assays. Nec-1 (30 µM) was added 1 h 
before zVAD-fmk. Results are presented as the mean value ± SEM of three independent experiments 
performed in duplicates and normalized to control cells (ǂ p ˂ 0.001 vs. control; ¥ p < 0.001 vs. LPS; * 






zVAD-fmk promotes necrosome assembly in BV2 microglia cells  
 RIP1 and RIP3 assembly into the necrosome is crucial for necroptosis 
activation (Li J et al, 2012). Thus, we evaluated the presence of RIP1/RIP3 in detergent 
insoluble protein fractions of BV2 cells upon zVAD-fmk treatment with or without LPS. As 
shown in Figure 8, RIP1 and RIP3 were sequestered in the insoluble fraction in cells pre-
treated with LPS for 24 h and then incubated with zVAD-fmk for additional 5 h, thus 
confirming functional necrosome assembly and, consequently, necroptosis activation (Fig. 
8A). Cells solely treated with zVAD-fmk had no RIP1 and RIP3 in this fraction, suggesting 
that at this time-point zVAD-fmk is still not capable of inducing necroptosis (Fig. 8A). 
Curiously, more than 5 h of LPS/zVAD-fmk resulted in complete loss of plasma membrane 








Figure 7. LPS exposure increases RIP1 and RIP3 total protein levels. BV2 cells were pre-treated 
with 100 ng/mL LPS for 24 h and then exposed to the pan-caspase inhibitor zVAD-fmk (25 µM) for 
additional 24 h. Nec-1 (30 µM) was added 1 h before zVAD-fmk. Total protein lysates were prepared 
for Western blot analysis of RIP1, RIP3 and MLKL. -actin was used as loading control. 
 
To corroborate MTS and LDH assay data and confirm necroptosis activation in 
that same conditions, we incubated BV2 cells with zVAD-fmk for 24 h. The results showed 
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the presence of RIP1 and RIP3 in the insoluble fraction, thus confirming necrosome 
assembly, indicating that zVAD-fmk induces necroptosis in BV2 cells after 24 h (Fig. 8B). 
Importantly, addition of Nec-1 abolished RIP1 and RIP3 sequestration in the insoluble 
fraction, both in zVAD-fmk and LPS/zVAD-fmk-treated cells, thus confirming that the marked 
increase in total protein levels had no functional consequence in terms of induction of 
necroptosis (Fig. 8). Taking these results into account, BV2 cells exposed to zVAD-fmk are a 
robust in vitro model of microglia necroptosis, which is fully reverted when RIP1 kinase 
activity is inhibited by Nec-1.  
  
Figure 8. zVAD-fmk treatment only induces necrosome assembly at 24 h of incubation. (A) BV2 
cells were pre-treated with 100 ng/mL LPS for 24 h and then exposed to the pan-caspase inhibitor 
zVAD-fmk (25 µM) for additional 5 h. Nec-1 (30 µM) was added 1 h before zVAD-fmk. (B) BV2 cells 
were co-treated with zVAD-fmk (25 µM) plus Nec-1 (30 µM) for 24 h. Detergent soluble and insoluble 
fractions were prepared for Western blot analyses of RIP1 and RIP3. β-actin was used as loading 
control. 
 
Screening for potential inhibitors of necroptosis 
Tool compounds blocking necroptosis have been developed since 2005; 
however, to date, no necroptosis inhibitors are in clinical use. In this regard, the identification 
of new molecules with potential for inhibiting this type of cell death is strongly needed.  
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Here, we used our established BV2 cell line in vitro model to screen two in-house 
chemical libraries of new compounds, designed as potential inhibitors of necroptosis. The 
first family of twenty compounds tested had no impact in zVAD-fmk-induced cell death in this 
cell line, as observed by MTS metabolism (Fig. 9). 
 
Figure 9. The first chemical library of twenty compounds does not modulate necroptosis in 
BV2 microglial cell line. BV2 cells were incubated with zVAD-fmk (25 µM); zVAD-fmk (25 µM) plus 
Nec-1 (30 µM); compounds (30 µM) or zVAD-fmk (25 µM) plus compounds (30 µM) for 24 h. Cell 
metabolic activity was determined by MTS metabolism. The results are presented as the mean value ± 
SEM of three independent experiments performed in duplicates and normalized to control BV2 cells (ǂ 
p ˂ 0.001 vs. control no addition; ¶ p ˂ 0.001 vs. control zVAD-fmk). 
 
However, we were able to identify one hit within the second family of twenty-one 
compounds (Oxa1-21). Oxa12 significantly reduced zVAD-fmk-mediated cell death, as 
observed by MTS and LDH assays (p ˂ 0.05) (Fig. 10). Notably, treatment of BV2 cells with 
Oxa12 increased cell viability (p ˂ 0.05) and decreased membrane permeabilization (p ˂ 







Figure 10. Oxa12 modulates necroptosis in the BV2 microglial cell line. BV2 cells were incubated 
with zVAD-fmk (25 µM); zVAD-fmk (25 µM) plus Nec-1 (30 µM); compounds (30 µM) or zVAD-fmk (25 
µM) plus compounds (30 µM) for 24 h. Cell metabolic activity was determined by MTS metabolism and 
cell membrane integrity was determined by LDH activity. Data are presented as the mean value ± 
SEM of three independent experiments performed in triplicates and normalized to control BV2 cells (ǂ 
p ˂ 0.001 vs. control no addition; ¶ p ˂ 0.001 vs. control zVAD-fmk; ¥ p ˂ 0.01 vs. control zVAD-fmk; * 
p ˂ 0.05 vs. control zVAD-fmk). 
 
Oxa12 modulates necroptosis in the BV2 microglial cell line 
To further characterize Oxa12 activity, drug toxicity was assessed by determining 
its half maximal inhibitory concentration (IC50). We incubated BV2 cells with different 
concentrations of Oxa12 ranging from 1 to 150 µM, and determined that this compound 
alone did not induce any cytotoxicity in BV2 cells, even at high concentrations (IC50>130 µM) 
(Fig. 11A). Additionally, we also determined its half maximal effective concentration (EC50) for 
inhibiting necroptosis using concentrations from 0.1 to 50 µM. Our results showed that 
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Oxa12 was effective at inhibiting zVAD-fmk-induced necroptosis, with an EC50 of 1.422 µM 
(Fig. 11B).  
 
Figure 11. Oxa12 is effective at inhibiting zVAD-fmk-induced necroptosis without toxicity. (A) 
BV2 cells were incubated with different concentrations of Oxa12 (1, 2.5, 5, 10, 30, 50, 100 and 150 
µM) for 24 h. (B) BV2 cells were incubated with different concentrations of Oxa12 (0.1, 0.5, 1, 2.5, 5, 
10, 30, and 50 µM) plus zVAD-fmk (25 µM) for 24 h. Cell metabolic activity was determined by MTS 
metabolism.  The results are presented as the mean value ± SEM of three independent experiments 
performed in duplicates and normalized to vehicle control (DMSO). 
 
 
Figure 12. In silico molecular docking calculations for Oxa12. (A) Optimal poses obtained inside 
RIP1 active site (grey) for Oxa12 (represented in stick model and colored blue) compared with 
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crystallographic ligand 1-aminoisoquinoline inhibitor (PDBID: 4NEU) (yellow). (B) Oxa12 and 4NEU 
co-crystallized inhibitor interacting with Asp156, Leu157, Met67 and Met95. Docking calculations were 
performed using the X-ray structure obtained for RIP1 complexed with 1-aminoisoquinoline inhibitor at 
resolution of 2.57 Å, PDBID: 4NEU, by the GOLD 5.2 software. 
 
Finally, to explain the observed biological activity and to get insight into the 
mechanism of action of Oxa12 at the molecular level, we performed in silico molecular 
docking calculations for Oxa12 inside the RIP1 kinase domain using the X-ray structure 
obtained for this enzyme complexed with 1-aminoisoquinoline type II kinase inhibitor (Harris 
PA. ACS Med. Chem. Lett 2013, 4(12)). The docking studies were conducted by Prof. Rita 
Guedes from the Medicinal Chemistry group within iMed.ULisboa. Our results showed that 
without any constrain (e.g. a covalent bond), Oxa12 is occupying a pose similar to the co-
crystallized inhibitor, with the phenyl rings from both compounds almost superposed, thus 
suggesting a similar interaction (Fig. 12A). However, Oxa12 is slightly rotated when 
compared with the crystallographic ligand, being close to Asp156, Leu157, Met67 and 
Met95, which may enable important hydrogen bonds and π interactions. Importantly, Oxa12 
showed increased interaction distances in comparison to the crystallographic inhibitor (Fig. 
12B).  
 
Oxa12 inhibits necroptosis in the BV2 microglial cell line 
In order to determine the effect of Oxa12 in the necroptotic signaling pathway, we 
co-incubated cells with zVAD-fmk plus Oxa12 for 24 h and evaluated both necrosome 
assembly and MLKL S358 phosphorylation in detergent insoluble fractions. MLKL 
phosphorylation at T357/S358 residues is mediated by RIP3 during necroptosis, leading to 
51 
 
MLKL oligomerization, thus being an excellent marker of necroptosis commitment (Ofengeim 
D et al, 2015; Wang H et al, 2014). 
As depicted in Figure 8 and Figure 13, we confirmed that at this time-point, 
incubation with zVAD-fmk significantly increased the levels of RIP1 and RIP3 in the insoluble 
fraction (p ˂ 0.05), thus suggesting functional necrosome assembly and necroptosis 
activation. Additionally, the levels of MLKL S358 phosphorylation were also significantly 
increased (p ˂ 0.05) (Fig. 13). Nec-1 incubation totally abrogated both conditions (p ˂ 0.05). 
Of note, Oxa12 prevented all necroptosis-associated events, including RIP1/RIP3 functional 
necrosome assembly and MLKL S358 phosphorylation (p ˂ 0.05) (Fig. 13).  
Finally, we analyzed BV2 morphology after zVAD-fmk treatment with and without 
Nec-1 and Oxa12. As expected, both compounds reverted zVAD-fmk-induced cell 
morphology (Fig. 14). Taken together, these results implicate Oxa12 as a strong inhibitor of 



















Figure 13. Oxa12 modulates necroptosis in a microglial cell line. BV2 cells were incubated with 
zVAD-fmk (25 µM); zVAD-fmk (25 µM) plus Nec-1 (30 µM) or zVAD-fmk (25 µM) plus Oxa12 (30 µM) 
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for 24 h. Detergent soluble and insoluble protein fractions were prepared for Western blot analysis of 
RIP1, RIP3, MLKL and p-MLKL. Representative immunoblots are presented with the respective 
densitometric analysis. -actin was used as loading control. Values are expressed as mean ± SEM of 

















Figure 14. Oxa12 reverts zVAD-fmk-induced cell morphology. BV2 cells were incubated with 
zVAD-fmk (25 µM); Nec-1 (30 µM); zVAD-fmk (25 µM) plus Nec-1 (30 µM); Oxa12 (30 µM) or zVAD-
fmk (25 µM) plus Nec-1 (30 µM) for 24 h. Microscopy images were taken at 100x with a Primo Vert 
microscope.  
 
Oxa12 reduces TNF-α gene expression and secretion 
Necroptosis is a proinflammatory type of cell death, due to the release of 
intracellular components called DAMPs to the extracellular space where innate immune cells 
are located, thus enhancing inflammation (Moriwaki K et al, 2013). Therefore, after 
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confirming that Oxa12 inhibited necroptosis in BV2 cells, we hypothesized that this inhibition 
may also contribute to decreased inflammation.  
In this respect, other studies have reported that zVAD-fmk-induced necroptosis is 
dependent on the production and autocrine secretion of TNF-α (Wu YT et al, 2011). Thus, we 
assessed TNF-α secretion levels by ELISA as well as expression of proinflammatory genes, 
including COX2, IL-1β, IL-6, NLRP3 and TNF-α by qRT-PCR.  
The results showed that zVAD-fmk treatment for 24 h significantly enhanced 
TNF-α secretion levels, with an increase of approximately 2-fold relative to control cells (p ˂ 
0.05). In contrast, Nec-1 fully reverted TNF-α secretion to control levels (p ˂ 0.05) and more 
importantly, Oxa12 significantly reduced its levels by approximately 1.5-fold (p ˂ 0.05) (Fig. 
15). All together, these findings suggest that autocrine secretion of TNF-α is a key step of 
zVAD-fmk-induced necroptosis. Oxa12 induces a marked decrease in TNF-α secretion, 











Figure 15. Oxa12 decreases TNF-α secretion levels. BV2 cells were incubated with zVAD-fmk (25 
µM); Nec-1 (30 µM), zVAD-fmk (25 µM) plus Nec-1 (30 µM); Oxa12 (30 µM), or zVAD-fmk (25 µM) 
plus Oxa12 (30 µM) for 24 h. Secreted TNF-α was measured with a murine TNF-α ELISA kit. Results 
are presented as mean ± SEM from three independent experiments, and expressed as absolute TNF-
α levels (ǂ p ˂ 0.05 vs. control and * p ˂ 0.05 vs. zVAD-fmk). 
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Regarding the transcription of proinflammatory genes, the results showed that 
exposure of BV2 cells to zVAD-fmk for 24 h resulted in a significant increase of TNF-α and 
IL-1β gene expression (p ˂ 0.001), which was totally reverted upon Nec-1 incubation (p ˂ 
0.05 and p ˂ 0.001, respectively) (Fig. 16). Importantly, Oxa12 also reduced TNF-α gene 
expression by about 40% (p ˂ 0.05), which was in accordance with the results obtained in 
the ELISA assay. Surprisingly, incubation with Oxa12 had an opposite effect in IL-1β 
expression (p ˂ 0.05) increasing transcript levels more than 2-fold (Fig. 16). Relatively to 
COX2 and NLRP3, the results did not show any significant variation (Fig. 16), and the 





















































Figure 16. Oxa12 decreases TNF-α gene expression. BV2 cells were treated with zVAD-fmk (25 
µM); Nec-1 (30 µM), zVAD-fmk (25 µM) plus Nec-1 (30 µM); Oxa12 (30 µM), or zVAD-fmk (25 µM) 
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plus Oxa12 (30 µM) for 24 h. mRNA levels of proinflammatory mediators (TNF-α, IL-1β, COX2 and 
NLRP3) were measured by RT-PCR. Results are expressed as mean ± SEM from three independent 
experiments (ǂ p ˂ 0.001 vs. control; ¶ p ˂ 0.001 vs. zVAD-fmk; * p ˂ 0.05 vs. zVAD-fmk). 
 
Oxa12 modulates zVAD-fmk-induced JNK and p38 MAPK signaling activation and 
increases IκB phosphorylation 
To further dissect which inflammatory pathways Oxa12 specifically targets, we 
evaluated JNK (Thr183/Tyr185) and p38 (Thr180/Tyr182) phosphorylation, two important 
MAPK signaling pathways involved in inflammation (Kim EK et al, 2010). In addition, we also 
evaluated phosphorylation of protein kinase B, also known as Akt (Ser473). Indeed, others 
have shown that JNK and Akt, when activated, have important roles in necroptosis, where 
they are involved in the production and autocrine secretion of TNF-α (Christofferson DE et al, 
2012). Importantly, phosphorylation of these proteins is strongly related with their activation 
(Wu YT et al, 2011). NF-κB activation, here evaluated by IκB (Ser32/36) phosphorylation, is 
also involved in inflammation and cell survival (Rubio-Perez JM et al, 2011). IκB 
phosphorylation leads to its own degradation and, consequently, the release and nuclear 
translocation of NF-κB where it exerts activity as a transcription factor. 
As observed in Figure 17, incubation of BV2 cells with zVAD-fmk for 24 h induced 
a significant increase in JNK and p38 phosphorylation (p ˂ 0.01 and p ˂ 0.001, respectively), 
thus suggesting activation of these two signaling pathways. By contrast, Nec-1 fully reverted 
JNK and p38 phosphorylation to control levels (p ˂ 0.01 and p ˂ 0.001, respectively) (Fig. 
17). Importantly, Oxa12 significantly decreased both JNK (p ˂ 0.05) (Fig. 17A) and p38 
phosphorylation levels (p ˂ 0.001) (Fig. 17B), when compared to zVAD-fmk-treated cells. 
Regarding Akt activation, no significant changes were observed in these experimental 
conditions (Fig. 18). Nevertheless, zVAD-fmk treatment appeared to reduce IκB 
phosphorylation (p ˂ 0.05), which was counteracted by Nec-1 (p ˂ 0.05). Addition of Oxa12 
58 
 
to the culture media also increased IκB phosphorylation (p ˂ 0.05), thus suggesting NF-κB 












Figure 17. Oxa12 decreases zVAD-fmk-induced JNK and p38 MAPK activation. BV2 cells were 
treated with zVAD-fmk (25 µM), zVAD-fmk (25 µM) plus Nec-1 (30 µM) or zVAD-fmk (25 µM) plus 
Oxa12 (30 µM) for 24 h. (A) Representative immunoblots of p-JNK (Thr183/Tyr185) and total JNK are 
presented, together with the respective densitometric analysis of the p-JNK/JNK ratio. (B) 
Representative immunoblots of p-p38 (Thr180/Tyr182) and total p38 are presented with the respective 
densitometric analysis of the p-p38/p38 ratio. Values are expressed as mean ± SEM of three 
independent experiments (ǂ p ˂ 0.001 vs. control; ¥ p ˂ 0.001 vs. zVAD-fmk; § p ˂ 0.01 vs. control; ¶ 
p ˂ 0.01 vs. zVAD; * p ˂ 0.05 vs. zVAD). 
 
Figure 18. zVAD-fmk incubation does not affect 
Akt phosphorylation in BV2 cells. BV2 cells were 
incubated with zVAD-fmk (25 µM), zVAD-fmk (25 µM) 
plus Nec-1 (30 µM) or zVAD-fmk (25 µM) plus Oxa12 
(30 µM) for 24 h. Representative immunoblots of p-Akt 
(Ser473) and total Akt are presented together with the 
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respective densitometric analysis of the p-Akt/Akt ratio. Results are expressed as mean ± SEM from 



















Figure 19. Oxa12 increases IκB phosphorylation levels when compared to zVAD-fmk-treated 
cells. BV2 cells were incubated with zVAD-fmk (25 µM), zVAD-fmk (25 µM) plus Nec-1 (30 µM) or 
zVAD-fmk (25 µM) plus Oxa12 (30 µM) for 24 h. Representative immunoblots of total NF-κB, p-IκB 
(Ser32/36) and total IκB are presented together with the respective densitometric analysis. -actin was 
used as loading control. Results are expressed as mean ± SEM from three independent experiments 


















































































Neurological disorders are an important cause of mortality and represent 12% of 
total deaths worldwide. The prevalence of neurodegenerative diseases, in particular, is 
expected to continue to enlarge, mostly due to the increase in the lifespan of the general 
population, which constitutes a major health economic challenge for Europe.  
Neurodegenerative diseases are mainly characterized by progressive 
neurodegeneration, presence of abnormal protein assemblies, oxidative stress and 
neuroinflammation. Currently, the treatments available are ineffective. Therefore, new 
interventions that slow or stop neurodegeneration are an urgent, unmet need.  
Although apoptotic cell death is frequently implicated in neurodegeneration, 
necroptosis has been recently described as a prominent player in neurodegenerative 
diseases pathobiology (Vandenabeele P et al, 2010). Necroptosis is a caspase-independent 
form of regulated cell death, executed via activation of RIP1 and RIP3, being negatively 
regulated by caspase-8 (Vercammen D et al, 1998). Neuroinflammation is also a pathological 
hallmark of neurodegenerative diseases, where microglia have a fundamental role regulating 
both innate and adaptive immune responses (Rubio-Perez JM et al, 2011). 
Throughout the recent literature, the role of necroptosis has been studied in the 
pathogenesis of several diseases, with the results indicating necroptosis inhibition as an 
improvement factor (He S et al, 2009; Takemoto K et al, 2014). Regarding the CNS, most 
studies implicate necroptosis in neuronal death and refer inhibition of necroptosis as a 
beneficial event (Degterev A et al, 2005; Liu S et al, 2014; Northington FJ et al, 2011; Xu X et 
al, 2007). Conversely, other authors demonstrated that primary microglia treated with 
caspase inhibitors undergo necroptosis, and this mechanism has been interpreted as a 
strategy for preserving neurons (Fricker M et al, 2013). This raises the question whether 
protection against necroptotic microglial cell death might also be beneficial in the CNS given 
that necroptotic cell death often results in inflammation. Indeed, it was recently shown that in 
certain pathological conditions, such as MS, microglia present a strong defect in caspase-8 
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activation, which may promote inflammation through activation of necroptosis, thus 
contributing to the progression of the disease (Ofengeim D et al, 2015). In these cases, 
targeting the necroptotic machinery may be useful to attenuate microglial-mediated 
inflammation and cell death. 
In this work, we used the murine BV2 microglia cell line as a new and robust in 
vitro model for screening potential modulators of microglia necroptosis. BV2 cells are derived 
from raf/myc-immortalized murine neonatal microglia and are the most frequently used cells 
to model primary microglia (Lund S et al, 2005).  
Our results showed that BV2 cells undergo necroptosis after 24 h incubation with 
the pan caspase inhibitor, zVAD-fmk, which is in agreement with previous studies reporting 
that zVAD-fmk induces necroptosis in L929 cells (Chistofferson DE et al, 2012; Wu YT et al, 
2011). However, pre-incubation with LPS accelerated or potentiated the death mechanism, 
thus implicating necroptosis in this inflammatory context. Indeed, we observed a decrease of 
~30% in MTS metabolism when cells were pre-incubated with LPS for 24 h and, then, 
incubated with zVAD-fmk for additional 24 h, while no differences were observed in LDH 
activity. These results suggest that cell membrane permeabilization and leakage of 
intracellular components, such as LDH, may be an initial step in the necroptotic cascade. In 
contrast, ROS production and mitochondria dysfunction appears to contribute indirectly to 
late-stage necroptosis (Wang H et al, 2014; Chen X et al, 2014; Tait SW et al, 2013). In 
addition, we observed that, while LPS/zVAD-fmk co-treatment induces necrosome assembly 
after 5 h incubation, zVAD-fmk alone induces necrosome assembly only after 24 h.  
LPS is a well-known TLR4 agonist that was already shown to induce RIP3-
dependent necroptosis, after caspase inhibition (Fricker M et al, 2013). On the other hand, it 
is known that zVAD-fmk triggers the production of TNF-α at the transcriptional level, and 
subsequently the autocrine secretion of this cytokine, which in turn may activate TNFR to 
induce necroptosis (Wu YT et al, 2011). Thus, it was not surprising that zVAD-fmk alone 
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induced necroptosis at later time-points. In contrast, the RIP1-specific inhibitor, Nec-1, here 
used as a positive control of necroptosis inhibition, fully reverted cell death to control levels in 
all conditions tested, thus implicating RIP1-dependent necroptosis as the death mechanism. 
Additionally, the reversion of necrosome assembly induced by Nec-1 incubation confirmed 
the importance of this molecular platform as a cell death inducer in our model.  Overall, BV2 
cells exposed to zVAD-fmk represent a robust in vitro model of microglia necroptosis, along 
with full reversion of all necroptotic processes when RIP1 kinase activity is inhibited by Nec-
1. 
In 2005, a phenotypic screening for small molecules that inhibit TNF-induced cell 
death identified the first necroptosis inhibitor, Nec-1, which inhibits RIP1 kinase activity 
(Degterev A et al, 2005). Since then, several necroptosis inhibitors have been described, 
including RIP1, RIP3 and MLKL inhibitors. However, all compounds identified so far show 
several limitations. Nec-1, for instance, is highly effective in inhibiting necroptosis 
(EC50=0.494 µM); however, it has inadequate pharmacokinetic properties including very short 
in vivo half-life of approximately 1 h, along with reduced solubility. In addition, it was recently 
shown that Nec-1 has non-specific activities against IDO, an enzyme involved in 
inflammation, as well as against serine/threonine-protein kinase 1 (PAK1) and protein kinase 
cAMP(PKA)-dependent catalytic subunit, indicating Nec-1 potential off-target activity (Jagtap 
PG et al, 2007; Vandenabeele P et al, 2013). Regarding RIP3 inhibitors, all compounds 
described so far present caspase-independent cytotoxicity, along with the ability to induce 
apoptosis (Mandal P et al, 2014). Finally, NSA, a known MLKL inhibitor, inhibits necroptosis 
by blocking human MLKL phosphorylation, but not the rodent homolog, invalidating 
pharmacological, pharmacokinetic and toxicity preclinical testing (Sun L et al, 2012). In sum, 
although tool compounds blocking necroptosis have been developed, no necroptosis 
inhibitors are in clinical use to date. Therefore, the discovery of new specific and potent 
pharmacologic inhibitors of necroptosis is of utmost importance. 
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In this study, we screened two libraries of new compounds from two different 
families that potentially modulate necroptosis. In the first family of compounds, none of the 
molecules were able to modulate necroptosis. However, in the second family of compounds, 
we identified one hit (Oxa12) that inhibits necroptotic cell death by approximately 40% 
relatively to zVAD-fmk-treated cells, being effective at low concentrations (EC50=1,422 µM) 
and without cytotoxicity associated. Further, Oxa12 inhibited all necroptosis-associated 
events, including necrosome assembly and MLKL S358 phosphorylation, two important 
markers of necroptosis commitment. Importantly, the docking pose of Oxa12 inside RIP1 
active site is similar to the co-crystallized 1-aminoisoquinoline inhibitor, suggesting its 
potential as necroptosis inhibitor. 
To further characterize the mechanism of action of Oxa12 and because 
necroptosis is an inflammatory type of cell death, we hypothesized that necroptosis inhibition 
by Oxa12 could also result in decreased inflammation. Our results showed that BV2 cells 
exposed to zVAD-fmk presented increased levels of TNF-α gene expression and cytokine 
secretion. These findings were in accordance with previous studies reporting the production 
and autocrine secretion of TNF-α as a crucial factor in zVAD-fmk-induced necroptosis 
(Hitomi J et al, 2008; Wu YT et al, 2011). Moreover, zVAD-fmk also induced IL-1β gene 
expression, thus confirming the proinflammatory potential of necroptosis. Finally, no 
differences were detected in COX2 and NLRP3 transcription levels, which might be due to 
the involvement of IL-1β in the initiation of the inflammatory cascade, while COX2 and 
NLRP3 are mainly involved in later stages, being extensively regulated by other proteins and 
signaling cascades (Abderrazak A et al, 2015; Bakhle YS et al, 1996; Latz E et al, 2013). 
Similarly to what happens with Nec-1 (Chistofferson DE et al, 2012), treatment of 
BV2 cells with Oxa12 also reduced TNF-α gene expression and cytokine secretion levels. 
Importantly, inhibition of necroptosis by Nec-1 suggests that RIP1 kinase activity is required 
for TNF-α production, as previously reported (Christofferson DE et al, 2012). Nec-1 also 
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reverted IL-1β gene expression being indicated as an anti-inflammatory molecule (Nikseresht 
S et al, 2015). In contrast, we cannot rule out that inhibition of necroptosis by Oxa12 results 
in increased inflammation through a compensatory mechanism, as we observed a marked 
increase in IL-1β gene expression after Oxa12 incubation. However, IL-1β processing and 
activation is dependent on NLRP3 inflammasome and caspase-1 activity. NLRP3 
inflammasome assembly occurs in response to an inflammatory stimulus and leads to 
caspase-1 activation, which in turn mediates the cleavage of cytosolic pro-IL-1β into the 
mature and secreted proinflammatory cytokine (Baroja-Mazo A et al, 2014). Since we did not 
observe any modulation of NLRP3 gene expression, it is unlikely that Oxa12-mediated 
increase in IL-1β mRNA does translate into increased levels of secreted IL-1β. Still, further 
studies are needed to confirm these results. 
To better understand which inflammatory pathways are specifically targeted by 
Oxa12, we evaluated the activation of two MAPK signaling pathways, JNK and p38, as well 
as the activation of Akt. Recent studies have reported that JNK activation plays an important 
role during necroptosis in L929 cells downstream to RIP1 kinase (Christofferson DE et al, 
2012). Indeed, it has been demonstrated that zVAD-fmk induces activation of protein kinase 
C (PKC), which activates JNK, leading to the activation of transcription factor activating 
protein 1 (AP1) that, in turn, promotes TNF-α gene expression (Wu YT et al, 2011). 
Interestingly, it was also reported that RIP1 may interact with the E3 ubiquitin ligase EDD, 
and cIAP1, leading to JNK activation and consequently to specificity protein 1 (Sp1)-
dependent transcription of TNF-α (Christofferson DE et al, 2012). Importantly, increased 
TNF-α transcription may translate into elevated levels of this cytokine, which could induce 
necroptosis through TNFR activation (Wu YT et al, 2011). Our results are in line with these 
studies, since exposure of BV2 cells to zVAD-fmk induced high levels of JNK activation. This 
activation, in turn, may be related with the increase observed in TNF-α gene expression and 
cytokine secretion levels. By contrast, Nec-1 and Oxa12 abolished both JNK activation and 
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TNF-α gene expression and cytokine secretion levels, thus confirming the involvement of this 
signaling pathway in zVAD-fmk-induced necroptosis.  
Regarding p38, the results described so far are somehow contradictory. Some 
authors reported that this signaling pathway is not activated during necroptosis in L929 cells 
(Yu L et al, 2004). Conversely, others have shown that pharmacological inhibition of TNF-α-
induced necroptosis in L929 cells resulted in p38 activation, as well as inhibition of JNK (Ye 
YC et al, 2011). Here, we show that treatment of BV2 cells with zVAD-fmk induces a marked 
increase in p38 phosphorylation, which is fully reverted after Nec-1 and Oxa12 incubation. 
These findings suggest activation of this signaling pathway during zVAD-fmk-mediated 
necroptosis in BV2 cells. In addition, it is well known that both JNK and p38 MAPK pathways 
are involved in stress responses and inflammation. Indeed, these kinases are activated by 
several inflammatory mediators in different cell lines (Dhillon AS et al, 2007). Thus, it is 
possible that the intracellular components released by necroptotic cells may induce JNK and 
p38 MAPK activation.  
Furthermore, a recent study suggested that Akt is linked to necroptosis in L929 
cells, where it plays a key role in mediating TNF-α synthesis (Wu YT et al, 2009). Inhibition of 
Akt protected L929 cells from TNF-α-induced necroptosis (Jin S et al, 2007). Indeed, in some 
conditions, inhibition of Akt and its downstream substrate mechanistic target of rapamycin 
(mTOR) reduces TNF-α-induced necroptosis and triggers autophagy instead. This study also 
showed that Akt and mTOR activation is not induced by TNF-α or zVAD-fmk alone, but it 
requires stimulation by both TNF-α and zVAD-fmk (Liu Q et al, 2014). In contrast, others 
have demonstrated that zVAD-fmk alone is indeed capable of inducing Akt activation, with 
this activation being dependent on Thr308 phosphorylation, while no alterations were 
observed in Akt Ser473 phosphorylation (McNamara CR et al, 2013). In our work, we 
evaluated Akt Ser473 phosphorylation as a marker of Akt activation, which may explain the 
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absence of significant differences between the conditions tested. Nevertheless, further 
studies are needed to confirm these results. 
Finally, we determined NF-κB activation by evaluating IκB phosphorylation. 
Phosphorylation of IκB by IKK complex leads to its proteolysis and, consequently, to 
translocation of NF-κB dimers to the nucleus where they can induce the expression of target 
genes involved in inflammatory and pro-survival responses (Xiao G et al, 2001). Some 
studies have shown that inhibition of TNF-α-induced necroptosis may promote NF-κB 
activation (Wang D et al, 2013). Interestingly, mounting evidence disregards NF-κB signaling 
as a modulator of autocrine TNF-α expression upon zVAD-fmk exposure (Wu YT et al, 
2011). Our results are in accordance with these findings, since zVAD-fmk treatment strongly 
reduced IκB phosphorylation levels. By contrast, both Nec-1 and Oxa12 further increased IκB 
phosphorylation levels, when compared to zVAD-fmk treatment. Therefore, it is possible that 
zVAD-fmk incubation induces a switch between a pro-survival pathway mediated by NF-κB 
and the activation of the necroptotic signaling, while Nec-1 and Oxa12 have the opposite 
effect. 
Overall, we established a robust in vitro model of microglia necroptosis, based on 
the murine BV2 microglial cell line and identified a strong lead inhibitor of this type of 
regulated cell death. In addition, Oxa12 demonstrated to be efficient at decreasing TNF-α 
gene expression and secretion levels, as well as activation of important signaling pathways 
including JNK and p38 MAPK. Moreover, our compound is effective at switching a 
necroptotic to a pro-survival signaling pathway mediated by NF-κB activation. Thus, Oxa12 























In this work, we established a new in vitro model of microglia necroptosis, based on 
the murine BV2 cell line. We identified one lead compound (Oxa12) that strongly inhibits the 
necroptotic signaling pathway without cytotoxicity associated. In addition, Oxa12 decreases TNF-
α gene expression and secretion levels, as well as JNK and p38 MAPK activation, while 
increases IκB phosphorylation levels. These results suggest that Oxa12 is capable of inducing a 
switch from a necroptotic pathway to a pro-survival signaling mediated by NF-κB.  
Still, further studies are needed to determine which is the specific target of this 
compound in the necroptotic signaling pathway. Regarding this question, we are currently 
engaged in determining whether Oxa12 presents any off-target effects, which should be achieved 
by performing a chemical proteomic profile. Moreover, all the compounds tested in this work were 
dissolved in DMSO, which raises some concerns about their solubility. In this respect, we intend 
to evaluate Oxa12 aqueous solubility and, if necessary, optimize its molecular structure so that it 
can be used in vivo. Oxa12 pharmacodynamics, biodisponibility and half-life will be also 
ascertained. 
Regarding the role of Oxa12 in inflammation, it is important to clarify if Oxa12-induced 
transcription of IL-1β does translate into increased levels of IL-1β secretion. Moreover, further 
studies are required to evaluate the role of Akt activation in necroptosis, as well as the effect of 
Oxa12 in this signaling pathway, which might be attained by evaluating Akt phosphorylation in 
other residues including Thr308. To deepen the knowledge of the role of JNK and p38 in zVAD-
fmk-induced necroptosis, we will further study their downstream targets.  
Finally, it would be also interesting to confirm the protective effects of Oxa12 in 
primary cultures of microglia and in co-cultures of primary microglia and neurons. We intend to 
determine if Oxa12-mediated inhibition of microglia necroptosis translates into an improvement of 
neuronal survival, which might point to an important therapeutic strategy for neurodegenerative 
diseases. Currently, there is no cure for neurodegenerative diseases and the treatments available 
are merely symptomatic. Therefore, the discovery of new interventions that slow or stop 
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neurodegeneration and neuroinflammation are an urgent, unmet need. In this regard, modulation 
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